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ABSTRACT
Separation processes are of great importance in many industries, especially in those that
produce highly regulated products. Crystallization is commonly used as a purification
technique in many industries, but can have two drawbacks: the first is the reduced
selectivity when a structurally similar impurity is incorporated into the crystal lattice of
the target being crystallized; second is increased process time and cost related to
filtration and drying, a particular issue for intermediates that are crystallized and need to
be re-dissolved in a subsequent step. The aim of this thesis is to develop separation
processes to enhance the selectivity along with minimization of solids handling. Three
different approaches were studied: (1) the separation of impurities from solution by
selective impurity cocrystal formation where the cocrystal has a lower solubility than
that of the impurity alone; (2) the use of coformers to form impurity-coformer
complexes in solution followed by the crystallization of the desired compound; and (3)
the selective adsorption of the impurity in solution using functionalized self-assembled
monolayers on gold surfaces.
All three approaches were built on the concept of "molecular recognition". In the first
approach, the impurity was crystallized in its cocrystal form by the addition of a
coformer while the target remained solubilized for downstream processing. The
feasibility of this process was assessed using ketoprofen/ibuprofen as the model
target/impurity system. A strategy was established for selecting the optimal coformer,
concentration of the coformer, and solvent for the separation process. The amount of
ibuprofen was decreased from 6 wt% to 2.5 wt%.
In the second approach, impurity-coformer complexes that could no longer fit into the
crystal lattice of the target compound were formed by the addition of coformers. The
feasibility of this process was examined using three systems: benzamide/benzoic acid,
cinnamamide/cinnamic acid, and amoxicillin trihydrate/4-hydroxyphenylglycine system.
Using the two model systems (benzamide/benzoic acid and cinnamamide/cinnamic
acid), we demonstrated the feasibility of reducing the amount of the impurity
substituting into the target crystal lattice by adding coformers that could form cocrystal
with the impurity but not with the target compound. In these cases we knew in advance
that cocrystals of the impurity with particular coformers would form. The impurity
content in the target crystals was approximately 20% less using the coformer than
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without the coformer. We then tested this method using the amoxicillin trihydrate
(AMCT)/4-hydroxyphenylglycine (4HPG) system for which we had no advance
knowledge of coformers that could form cocrystals with 4HPG. In this case we were
able to identify coformers that substantially reduced the impurity content in amoxicillin
crystals. Their purities were even superior to the purity that would be obtained from two
crystallizations of the initial solution. A clear correlation between the level of
complexation and the purification results was shown in this system.
The goal of the third method was to adsorb the impurity in solution selectively using
functionalized self-assembled monolayers on gold surfaces. Gold surfaces were
functionalized using thiols with different tail groups that could form hydrogen bonds
with a functional group on the impurity. Three target/impurity systems and two thiols
were studied using this approach. Despite the reasonable concept and experimental
design, large standard deviation between the experiments performed under same
conditions was observed. No significant separation results were obtained.
Thesis Supervisor:
Allan S. Myerson
Title: Professor of Chemical Engineering
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1. INTRODUCTION
In many industries, separation processes are employed to recover and purify
intermediates and final products. In industries that manufacture strictly regulated
products with high quality, such as the biopharmaceutical and food industries, it is
essential to develop efficient and economical separation processes to meet their needs.
To do so, it is necessary for these processes to have high selectivity (purity), capacity
(maximum applicable amount of material) and recovery (yield). Liquid-liquid
extraction, chromatography, and crystallization are the most commonly used separation
processes in these industries. Each process has its advantages and disadvantages and is
applied based on specific needs.
Liquid-liquid extraction is operated based on differences in the distribution
coefficients of different compounds in immiscible solvents. It is affected by the
operating temperature and the phase behavior of the solvents, which change with the
presence of different solutes and diluents. This process has been used extensively to
refine petroleum and intermediates in the food and biopharmaceutical industries.
Commercialized liquid-liquid extraction processes usually involve multiple stages (up to
thousands of stages) to achieve the required selectivity and productivity. It is known (1)
to be the most economic process to separate a group of similar compounds; (2) to have
high concentrations of desired compounds; and (3) to be applied to separate temperature
sensitive compounds, for example, biologically active compounds that could lose
selectivity or decompose at elevated temperature. However, it cannot separate a group of
similar compounds into individual species and hence cannot be applied to systems in
which the impurity is structurally similar to the target compound.
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Chromatography is another commonly used separation technology. It is based on
the different affinity of different compounds to the chromatography resins. The process
is designed by selecting the proper resin, column, and mobile phases. It has been
developed to manufacture biopharmaceuticals and food products and for analytical use.
Besides the usual high-performance liquid chromatography (HPLC), alternatives like
gas chromatography (GC), thin-layer chromatography (TLC), supercritical fluid
chromatography (SFC), capillary electrophoresis (CE), and countercurrent
chromatography have been developed for different applications. Its advantages include
(1) excellent assay precision (±0.5%) and (2) wide applicability and commercial
availability for most applications. However, it can be time-consuming to develop an
appropriate resin and can become difficult when large diameter columns are required on
the industrial scale. In addition, it is hard to recover dilute effluent streams.1 2 Most
importantly, it is costly to apply chromatography in an industrial process.
Crystallization is often used in the intermediate and final stages of separation and
purification in the biopharmaceutical, food, and many other industries. This process can
determine the purity and physical properties of the product, such as its crystal
morphology, size distribution, and crystal structure. It can also affect the flowability,
filterability, tableting behavior, bioavailability, and stability of the product.3 To control,
optimize, and develop crystallization processes, it is essential to understand the
thermodynamic properties and kinetics of the process and of the product. Compared to
liquid-liquid extraction and chromatography, crystallization has a better balance between
cost and selectivity. However, it can potentially have two drawbacks: first, the
crystallization process can be time-consuming and costly when filtration and drying are
16
required, a particular issue when the intermediate is first crystallized and then re-
dissolved for subsequent steps; second, when a structurally similar impurity is present in
solution, the selectivity can be lower than desired if an impurity is incorporated into the
crystal lattice of the target compound. In these cases, additional crystallizations, which
reduce the impurity content but sacrifice the yield, are often performed.
This thesis focuses on developing new processes to separate structurally similar
impurities from target compounds while (1) avoiding re-dissolution of the target
compound and (2) enhancing the selectivity of the crystallization in the presence of
structural similar impurities. Three processes were studied: (1) separating impurities
from solution by selectively forming impurity cocrystals with low solubility; (2)
preventing the impurity from incorporating into the crystal lattice of the target
compound by selectively forming impurity-coformer complexes in solution, and (3)
selectively adsorbing impurities in solution using self-assembled monolayers (SAMs) on
gold surfaces.
The first approach aims to purify intermediates and involves the formation and
crystallization of an impurity-coformer cocrystal. A coformer that can form a cocrystal
with only the impurity but not with the target is chosen and added to the impurity/target
mixture. The impurity-coformer cocrystal is chosen because it has low solubility in the
solution mixture. The impurity cocrystal can then be crystallized from solution,
removing the impurity and leaving the target molecule in solution.
To develop this separation process, it is necessary to learn: (1) how to select
coformers that meet our criteria, (2) how much coformer should be added, and (3) what
solvent should be used. A strategy established for finding the optimal coformer,
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concentration of the coformer, and solvent for a specific intermediate/impurity system is
presented. The first step is to search through the Cambridge Structural Database (CSD)
to find promising coformers that form cocrystals with the impurity but not with the
intermediate. We are interested in reported heterosynthons where one component is a
functional group on the impurity; any coformer with a complementary functional group
that encourages the formation of a heterosynthon with the impurity is thus a candidate.
That is, the potential coformers include, but are not limited to, the ones known to form
cocrystals with the impurity. Second, experiments are performed to confirm that the
chosen coformers could selectively cocrystallize out the impurity from an
impurity/intermediate mixture. Then, the solubilities of the impurity and its cocrystals
are measured. The cocrystal solubility must be significantly lower than that of the
impurity alone and should show the potential to meet the separation standard (-10%
impurity level). If this criterion is met, then the coformer and solvent are deemed
effective. Otherwise, a different coformer and solvent pair is tested by measuring the
impurity and cocrystal solubilities. This process is repeated to establish the optimal
coformer and solvent. Finally, phase solubility diagrams (PSD) of impurity
concentration as a function of coformer concentration were constructed to determine the
optimal coformer concentration yielding the lowest impurity concentration after
cocrystal formation. In this work, ibuprofen (IBU) and ketoprofen (KETO) were chosen
as the model impurity and target intermediate. We demonstrated the possibility to
separate impurities from solution using selective impurity formation. The effectiveness
of the design strategy to optimize the separation process was also validated.
18
The second approach targets systems in which the target compound is
crystallized in the presence of an impurity that incorporates in the crystalline lattice. It is
often possible for an impurity to substitute into the crystal lattice of the target compound
because of their structural similarity.4 5 In this approach, a coformer that can form
cocrystals with the impurity but not with the target compound is added to the
impurity/target mixture to form an impurity-coformer complex in solution. We postulate
that (1) the coformers that can form cocrystals with the impurity should form complexes
with the impurity in solution and (2) because of steric effects, the impurity-coformer
complexes would no longer fit into the crystal lattice of the target compound. By adding
coformers, the amount of impurity available to incorporate in the crystalline lattice is
reduced and thus the crystalline product obtained should have an increased purity.
To confirm that the purification was due to the complexation in solution, we
estimated the binding constants of the complexes and used them as indicators of the
level of complexation. Phase solubility diagrams for cocrystal systems were used to find
the stoichiometry and the binding constants for these complexes in equilibrium with
cocrystals.6 -1 With different combinations of cocrystal stoichiometry, complex
stoichiometries, and the binding constants of the complexes, the solubility of the
cocrystal is a unique function of the coformer concentration.'' 8 Benzoic acid/benzamide
(BA/BAM) and cinnamic acid/cinnamamide (CA/CAM) were chosen as our model
impurity/target systems. We were able to demonstrate the possibility of purifying
structurally similar compounds by adding coformers that can form cocrystals with the
impurity.
19
This approach was further studied using a real target/impurity system,
amoxicillin trihydrate (AMCT)/4-hydroxy-D-phenylglycine (4HPG), for which no
cocrystals of the impurity compound had been reported. A cocrystal screen of a series of
coformers was conducted with both the impurity and the target compound using solid
state grinding. Coformers that could form cocrystals with 4HPG but not with AMCT
were selected for further study. Separation experiments were performed with the
presence of these selected coformers. Our results further demonstrated the effectiveness
of purifying the target by adding coformers that can form cocrystals with the impurity.
The third approach has a similar separation mechanism to the first two: to choose
a functional group that can form hydrogen bonding with the functional group on the
impurity but not with the functional group on the target. Thiols with different functional
groups were chosen and attached to gold surfaces. Ideally, these functionalized gold
surfaces should selectively adsorb the impurity and leave a purified solution. Three
impurity/target compound systems were studied: IBU/KETO in toluene, BA/BAM in
ethanol and CA/CAM in ethanol. Two thiol molecules were chosen to bind the impurity
selectively: 2-mercapto benzimidazole and 4-mercapto pyridine. After initial promising
results shown in previous work, carefully repeated experiments show no significant
separation in all three systems. We concluded that this result is presumably due to the
lack of SAMs selectivity for impurities.
In this work, we successfully demonstrated the possibility to (1) separate the
impurity from solution using selective impurity cocrystal formation and (2) purify
structurally similar compounds by adding the proper coformers. The effectiveness of the
second approach was further verified using the AMCT/4HPG system. With these two
20
approaches, we can successfully (1) decrease the usage of multi-stage crystallization and
re-dissolution steps and (2) enhance the selectivity of separation methods.
21
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2. BACKGROUND
2.1 Definition of Cocrystals
The definition of cocrystals has been debated for over 160 years. At first,
cocrystals were defined as homogeneous crystalline materials composed of at least two
components held together through non-covalent interactions. These components could
be solid, liquid, gas, or a combination of all. The most common non-covalent
interactions are ionic, hydrogen bonding and van der Waals forces. In 2005, Aaker5y
suggested cocrystals are "made from reactants that are solids at ambient temperature".12
This definition eliminates the compounds classified as clathrates and inclusion
compounds (where the guest molecules are solvents and gas). In addition, salts are
considered as a different class of materials. Therefore, most people classify the most
common multi-component crystalline materials into three categories: salts, solvates (or
hydrates), and cocrystals (Figure 2-1).13 Solvates (or hydrates) are active pharmaceutical
ingredients (APIs) and solvents (or water) held together through non-covalent
interactions while all components in salts and cocrystals are solid. In addition, while the
components in salts are the API and its counter ion, cocrystals are composed of neutral
molecules. In our research, we define cocrystals as a homogeneous crystalline material
composed of a neutral target and a neutral coformer held together through non-covalent
bonds.
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salt solvate or hydrate cocrystal
= API E = counter- y = water/ M = neutral
ion solvent guest
Figure 2-1 Most Common Multi-component Crystalline Materials: Salts, Solvates or
Hydrates, and Cocrystals.13
2.2 Applications of Cocrystals
Pharmaceutical companies are interested in cocrystal engineering because of two
main reasons. First, the physiochemical properties of APIs can be modified while the
intrinsic activities of these drug molecules remain the same. For example, the solubility
and bioavailability of many APIs can be enhanced by forming their cocrystals. 14 In
addition, cocrystals can help achieve a high dissolution rate comparable to that of an
amorphous compound while maintaining the chemical and physical stability of the
crystalline form. 14 Second, the intellectual property protection of existing APIs can be
extended by forming their cocrystals. 15 Pharmaceutical companies used to extend the life
cycle of an existing drug by trying to find its polymorphs. However, the number of
polymorphs for an API is limited while the number of potential cocrystals is larger.
Therefore, to extend the life cycle of an existing drug, designing its cocrystals is
potentially a more efficient way than trying to find its polymorphs. Cocrystallization is
also considered an environmentally friendly way to produce crystals because it does not
require as much solvent as does the traditional crystallization (i.e. by grinding, see
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section 2.4). Cocrystallization also has the potential to be used in separation processes.
We can purify the API by adding its coformers and then discard these coformers before
the tablet formation. It is essential to understand the cocrystallization process so we can
design cocrystals with desired properties.
Urbanus et al. demonstrated its potential as a separation technique by removing
the product, cinnamic acid, from a fermentation reaction broth. The concentration of
cinnamic acid was decreased below the limiting concentration by forming its cocrystal
with 3-nitrobenzamide. Although this study looked at the cocrystal formation of the
desired product, there is little to no work in the literature concerning the selective
cocrystal formation of an impurity from an impurity/target mixture.
2.3 Design of Cocrystals
A typical cocrystal design process involves three steps: coformer selection,
computational analysis, and cocrystal characterization.16 For a target API, we are
interested in coformers with functional groups that can interact (i.e. form hydrogen
bonds) with the functional groups on the API. Common functional groups, such as
carboxylic acids, amides, and alcohols, are typically found to interact with one another
in cocrystals (Table 2-1).16 The most common intra/intermolecular interaction found in
cocrystals is hydrogen bonding. Etter has studied hydrogen bonds in cocrystals and use
them as design elements. 17 Instead of studying hydrogen bonds from an energy
viewpoint, she analyzed the cocrystal patterns as a result of intra/intermolecular
interactions and established general rules for hydrogen bonding. The three most
important rules are listed in Table 2-2.
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Table 2-1 Common Functional Groups Found in Cocrystals.1 6
Table 2-2 Hydrogen Bond General rules. 17
(1) All good proton donors and acceptors are used in hydrogen bonding
(2) If six-membered ring intramolecular hydrogen bonds can form, they will usually
do so in preference to forming intermolecular hydrogen bonds
(3) The best proton donors and acceptors remaining after intramolecular hydrogen-
bond formation form intermolecular hydrogen bonds to one another
In addition, she demonstrated the selectivity of hydrogen bonding in
cocrystallization by using pyridines as an example.17 She cocrystallized 4-
phenylpyridine and ethyl isonicotinate from a mixture of two carboxylic acids with
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Functional groups Typical supramolecular synthons used in crystal engineering
Carboxylic acid
(e.g., acetic acid, adipic acid, 0- H--0 O- H-N
benzoic acid, fumaric acid, R
maleic acid, malonic acid)
0-H-0 0--------H
Amides H
(e.g., nicotinamide and urea) N- H-----0 O- H-----0
----- H- N ----- H- N
H H
Alcohols
O- H-0
different pKa values and found that they only selectively cocrystallized with the
carboxylic acid with the smaller pKa (Table 2-3). The selectivity was demonstrated with
a mixture of 3, 4-dinitro-and 3, 5-dinitrobenzoic acids, whose difference in pKa is only
0.04. Similarly, Seaton et al. used Hammett constants to design acid/acid cocrystals. 8
Hammett constants are used to describe the electron withdrawing ability of the
substituents on benzoic acid derivatives. The more acidic the hydrogen, the larger the
Hammet constant. This study found that the greater the difference in Hammett constants,
the greater the chance these two acids would form cocrystals. By understanding
hydrogen bonding, we can select coformers for a target API. After potential coformers
are selected, we can search the target API in the Cambridge Structural Database (CSD)
and see if it has known cocrystals or heterosynthons that include the functional groups
on selected coformers. With this list of selected coformers, we can perform experiments
to confirm if they can form cocrystals with the target API. Finally, we can characterize
these cocrystals for their physical and chemical properties. With this cocrystal design
process, we can design cocrystals for a target API efficiently.
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Table 2-3 Selectivity in Cocrystallization of Pyridines with Mixture of Carboxylic
Acid.17
Pyridines in Cocrystal
0
N Hj\N
HO
Acid in cocrystal ApKa Uncomplexed Acid
0
H3C 0
02N
OH 2.35 N
H3C OH
0 2N
0
OH 0.74 0 2N-H
OH02
N
02N / - 0.41\ /
0.04
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CI
0 2N
0
OH
02N
2.4 Methods to Prepare Cocrystals
Different methods have been used to produce cocrystals. Sheikh et al. did a
survey on published research (Figure 2-2) and found that the three most common ways
are solution cocrystallization (including slow solvent evaporation, cooling and anti-
solvent), solid state grinding (including dry grinding and grinding with solvent-drop
addition) and cocrystallization from melts. 9
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Figure 2-2 Break Down of Techniques Used for Cocrystallization in Open Literature.19
We can produce cocrystals from melt using the Kofler method, which involves
four steps: (1) the two components are heated at a controlled rate; (2) the component
with the lower melting point melts and dissolves the other component to create a mixing
zone; (3) the sample is placed under polarizing microscope while being cooled and the
sample crystallizes inside the mixing zone to form cocrystals; (4) if you increase the
temperature, the eutectic compositions melt and create a liquid phase.20
We can also grind the API with a coformer to form cocrystals. Etter used dry
grinding as a technique to study hydrogen bonding in cocrystals. 7 She and Adsmond
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also found that dry grinding can not only reproduce the cocrystals obtained from
solution cocrystallization but can also produce new cocrystals.2 1 They found that for the
2-aminopyrimidine and succinic acid system, while solution cocrystallization can only
produce the 1:1 cocrystal, dry grinding can produce both 1:1 and 2:1 cocrystals.
Recently, studies have shown that adding drops of proper solvent during grinding can
help accelerate the cocrystallization process. Shan et al. used cyclohexane- 1,3cis,5cis-
tricarboxylic acid (CTA) as an example.2 2 Originally, it took an hour for 4,4'-bipyridine
to form cocrystals with CTA partially. By adding 0.05 ml methanol, cocrystallization
reached complete conversion in 20 minutes. Similarly, the process of cocrystallizing
CTA and 4,7-phenanthroline (fPh) was accelerated by adding methanol. Complete
conversion was reached in 5 minutes.
Solution cocrystallization is another commonly used technique to produce
cocrystals. Ling and Baker crystallized the derivatives of quinhydrone by slow
evaporation of the solvent and by producing a supersaturated solution through cooling.23
These techniques are still commonly used to produce cocrystals. It is also common to
utilize phase diagrams, such as ternary phase diagrams and phase solubility diagrams, to
aide solution cocrystallization. We will discuss the details of these phase diagrams in
section 2.5.
2.5 Thermodynamics of Cocrystals: Ternary Phase Diagrams and Phase
Solubility Diagrams
For separation purposes, it is essential to produce cocrystals by adding the
minimum amount of coformers to (1) trigger cocrystallization and (2) reach the highest
separation efficiency. It is also important to understand how the API solubility is affected
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by various amounts of coformers present in solution. Ternary phase diagrams have been
used to study the composition of API in its pure state and in its cocrystal state at a
constant temperature. A typical ternary phase diagram for a cocrystal system at a
constant temperature is shown in Figure 2-3. Points S, A, B, and C represent the pure
solvent, the pure API, the pure coformer, and the pure cocrystal respectively. Points D
and E represent the solubilities of the API and of the coformer, respectively, in the
specific solvent. Points F and G are eutectic points where the liquid phase is in
equilibrium with two solid phases (A and C) in the ternary phase diagram at a given
temperature and pressure. The solubility of the API at various amounts of the coformer
present in the solvent is presented by line DF. Similarly, the solubility of the coformer at
various amounts of the API present in the solvent is presented by line EG.
S
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Figure 2-3 A Typical Ternary Phase Diagram for a Cocrystal System.
Based on the nature of the system (the relatively solubility of the API and of the
coformer), we can divide the phase diagram into two categories: congruent and
incongruent (Figure 2-4). In a congruent system (Figure 2-4 (a)), if the starting material
is the pure cocrystal, no phase change would be observed during the process of adding
solvent to dissolve the cocrystal (start from point C and move to point S along line CS).
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On the other hand, in an incongruent system, if we add the solvent to the pure cocrystal,
we would observe a phase change. As shown in Figure 2-4 (b), we would observe the
formation of both the API (A) and the cocrystal (C) followed by the formation of the
pure API (A) solid phase. It is important to construct the phase diagram of the interested
cocrystal system to determine the best separation condition.
SO
D E
F E
A a A S
(a) (b)
Figure 2-4 Congruent (a) and Incongruent (b) Systems.
Although it is labor intensive to construct a ternary phase diagram, the
information it can provide is quite useful. The construction of a ternary phase diagram
includes two steps: identifying all solid phase regions and determining the liquidus curve
for each single solid phase region.24 Ternary mixtures with various compositions are
equilibrated at a set temperature and the resulting solid phase is analyzed by x-ray
powder diffraction (XRPD) and differential scanning calorimetry (DSC). Various
API/coformer stoichiometries are chosen to spread across the entire phase diagram and
the absolute solid amounts are enough to form slurries. After all solid phase regions are
identified, it is necessary to determine the composition of the saturated liquid
equilibrated with the pure solid phase. The composition can be measured by high-
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performance liquid chromatography (HPLC) or by gravimetric analysis. Eutectic points
are the intersection points of the liquidus curves. Chadwick et al. have used ternary
phase diagram construction to discover new cocrystal forms. The ternary phase diagram
for urea/glutaric acid in water was constructed (Figure 2-5) and a new stable polymorph
of 1:1 urea:glutaric acid cocrystal was found in addition to the known 2:1 urea:glutaric
acid cocrystal. 24 To understand a cocrystal system from a thermodynamic viewpoint, it is
necessary to construct a ternary phase diagram.
M% 11) Liquidus
2) Urea + liquid
3) Urea, 2:1 co-crystal + liquid (E1
composition)
4) 2:1 co-crystal + liquid
6) 2:1 co-crystal, 1:1 co-crystal + liquid
(E2 composition)
6) 1:1 co-crystal + liquid
7) 1:1 co-crystal, -lutaric acid liquid
5M (E3 composition)
E1 :) p-glutaric acid+ liquid
8
3 53 7
100%se a 1aii0% 25% 50% 75% 100%
Iue Blda-QitWiAid
Figure 2-5 Ternary Phase Diagram of Urea/Glutaric acid in Water at 25"C in mass%. 24
Since we intend to use cocrystallization in a separation process, it is important to
study the temperature effect on the cocrystal system. Therefore, instead of the traditional
ternary phase diagram, we adopted the phase solubility diagram, which has been
introduced as a graphical tool to present the ternary phase diagram in a x-y format. A
typical phase solublity diagram is shown in Figure 2-6 where [A] and [B] represent the
concentration of the API and the coformers respectively.6 The solid line is the solubility
of the cocrystal at various concentrations of B and the dotted line is the solublity of A at
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various concentrations of B. This phase solubility diagram is based on the following
assumptions: (1) A is less soluble than B, (2) A is less soluble than the cocrystal in
stoichiometric solutions (with respect to the cocrystal), (3) no complexation or
ionization of cocrystal components occurs in solution, and (4) the solubility of A is
independent of the concentration of B in solution.6 Four regions are separated by the
solubility curve of A and the A-B cocrystal. In region I, A is supersaturated but the A-B
cocrystal is undersaturated. Hence, we have pure A solids in this region. If the
concentration of B is increased, then both A and the A-B cocrystal become
supersaturated in region II. In region III, both A and the A-B cocrystal are undersaturated
while in region IV, A is undersaturated and the A-B cocrystal is supersaturated. The pure
A-B cocrystal can be obtained in this region. The intersection of the two solubility
curves is [B]tr where the solubility of A equals the solubility of the A-B cocrystal. The
path x to y shows the phase transition when the concentration of B is increased. The
point x represents the starting point where both A and the A-B cocrystal are
understurated. After the concentration of B is increased to the point y, the chemical
potential difference between point y and z drives the equilibrium to point z' by forming
A-B cocrystals. With the phase solubility diagram, we can plot multiple solubility curves
of the impurity at different temperatures in the same diagram. This method helps us to
envision the temperature effect. In addition, it is straight forward to calculate the amount
of coformers we need to add to the solution to achieve the desired separation. In
addition, the temperature effect on the cocrystal system can be presented and the
heating/cooling path can be illustrated.
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Figure 2-6 A Typical Phase Solubility Diagram.
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2.6 Scale Up of the Cocrystallization Process
To incorporate cocrystallization into the continuous manufacturing process, we
need to understand the criteria to scale up a cocrystallization process. As we mentioned
before, slow evaporation and grinding are the most common methods to produce
cocrystals. 19 They are useful in cocrystal screening but their scalability is limited. On the
other hand, solution cocrystallization (by cooling or adding anti-solvent) can be
incorporated into the continuous manufacturing process at a large scale. Sheikh et al.
used carbamazepine and nicotinamide as an example to demonstrate the scaling up
strategy.19 They were able to conduct a process at a 1 L scale with a yield of more than
90% and a 14 L/kg throughput. For a specific API/coformer system, the scaling up
strategy includes three steps: selecting a solvent, constructing a phase solubility diagram
to identify the thermodynamically stable regions and the saturated liquid curves, and
understanding the kinetics of the system. The following criteria of the solvents are
recommended: (1) coformers should have higher solubility than the API in the solvent
and (2) the critical concentration of the coformer at the operating temperature should be
significantly different from the solubility of the coformer. 19 A solvent with these
properties provides the widest pure cocrystal phase and the highest throughput. In a
continuous separation process, the solvent is constrained to be the solvent used in the
upstream synthesis process. However, we can add other solvents to form a solvent
mixture to achieve the desired solvent properties. After we select a solvent (or solvent
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mixture), we can construct the phase diagram for the API/coformer/solvent system.
The phase diagram can help us identify saturated liquid curves and stable solid regions.
We also need to study the kinetics of the system, including nucleation and crystal growth
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to develop seeding strategies and other parameters that may affect the cocrystallization
6process. Once we have all the information, we can start to design the process. A typical
scale-up cocrystallization process is illustrated in Figure 2-7. First, we need to make a
saturated solution of coformers at the harvest temperature (Tharvest, shown in blue). Then
we heat the solution up to the temperature where the coformer concentration is just
above the critical concentration. This temperature is the on-set temperature (Ton.set) at
which the process is going to be operated (shown in red). At this temperature, the API is
added to give us the maximum throughput. After the cocrystallization process, we can
add the anti-solvent to wash these cocrystals and hence remove them from the process.
For our separation purpose, it is essential to design the process with consideration of the
temperature effect.
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Figure 2-7 Proposed Process Trajectory (Thick Grey Arrow) in Three-Dimensional
Space Comprising Temperature, [Coformer] and [API].19
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3. THE SEPARATION OF IMPURITIES FROM SOLUTION BY
SELECTIVE IMPURITY COCRYSTAL FORMATION
3.1 Introduction
In this chapter, we demonstrate the possibility to separate impurities from
solution by selective impurity cocrystal formation. Ibuprofen (IBU) and ketoprofen
(KETO) were chosen as the model impurity/target system. Our strategy is to select
coformers capable of significantly decreasing the solubility of the impurity through
cocrystal formation, allowing for the removal of the impurity and for the retention of the
target in solution. To achieve this, coformers that can selectively form cocrystals with
the impurity but not with the target must be chosen. In addition, the impurity cocrystal
must exhibit decreased solubility compared to the impurity alone. The operating
conditions for the separation process, such as the coformer concentration and the solvent
system that result in the lowest impurity concentration, must be determined.
A strategy was established for finding the optimal coformer, concentration of the
coformer, and solvent for a specific impurity/target system. The first step is to search
through the Cambridge Structural Database (CSD) to find promising coformers that
form cocrystals with the impurity but not with the target. We are interested in reported
heterosynthons where one component is a functional group on the impurity; any
coformer with a complementary functional group that encourages the formation of a
heterosynthon with the impurity is thus a candidate. That is, the potential coformers
include, but are not limited to, the ones known to form cocrystals with the impurity.
Second, experiments are performed to confirm that the chosen coformers could
selectively crystallize out the impurity in its cocrystal form from an impurity/target
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mixture. Then, the solubilities of the impurity and its cocrystals are measured. The
cocrystal solubility must be significantly lower than that of the impurity alone and
should show the potential to meet the separation standard (-10% impurity level). If this
criterion is met, then the coformer and solvent are deemed effective. Otherwise, a
different coformer and solvent pair is tested by measuring solubilities of the impurity
and cocrystal. This process is repeated to establish the optimal coformer and solvent.
Finally, phase solubility diagrams (PSD) 6 of the impurity concentration as a function of
the coformer concentration are constructed to determine the optimal coformer
concentration yielding the lowest impurity concentration after cocrystal formation.
4,4'-bipyridine (BIPY) was chosen to be a potential coformer. To select the
optimal solvent, solubilities of KETO, IBU, and the IBU-BIPY cocrystal were measured
in two solvents: ethyl acetate (EtOAc) and a 50% water/ethanol (H20/EtOH) mixture.
The results suggested that a 50% H20/EtOH mixture is a better solvent than EtOAc.
Separation experiments were performed in both solvents and the results are presented in
Table 3-2. The results confirm that the 50% H20/EtOH mixture is the optimal solvent.
Phase solubility diagram data for the IBU-BIPY system were measured to find the
optimal BIPY concentration. Two approaches were investigated to improve the
separation result: the addition of cooling process and the use of nicotinamide (NCT) as
the coformer. Neither showed improvement for the separation process.
3.2 Materials and Methods
3.2.1 Materials
Ibuprofen (IBU, ACS reagent, >99.5%) was purchased from Sigma-Aldrich.
Ketoprofen (KETO, >98%), 4,4'-bipyridine (BIPY, 98%), nicotinamide (NCT, >99.5%,
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HPLC grade), and ethyl acetate (EtOAc, CHROMASOLV* Plus, for HPLC, 99.9%)
were purchased from Sigma-Aldrich and were used as received. Anhydrous ethanol (200
proof) was USP grade and was purchased from VWR. Acetonitrile (ACN,
CHROMASOLV* for HPLC >99%) and water (H20, CHROMASOLV* Plus for HPLC)
were purchased from Sigma-Aldrich and used for HPLC.
3.2.2 System selection
IBU and KETO were chosen as the model impurity and target, respectively. They
are both well-studied pharmaceutical compounds and are structurally similar (Figure 3-
1).
0 CH3
OH 0
0 OH
(a) (b)
Figure 3-1 Structures of (a) Ketoprofen and (b) Ibuprofen.
A search of the CSD for potential cocrystals of IBU led to the selection of BIPY
(Figure 3-2) as a coformer. A pre-existing cocrystal of IBU and BIPY can be found in
the CSD (refcode: HUPPAJ).2 6 The cocrystal has a 2:1 stoichiometry (IBU:BIPY). A
second search of the CSD found that there is no known cocrystal of KETO and BIPY.
We then demonstrated the selective cocrystal formation of IBU from an IBU/KETO
mixture using BIPY by preparing slurries of (a) 2:1 IBU:BIPY, (b) 2:1 KETO:BIPY and
(c) 2:2:1 KETO:IBU:BIPY. After allowing these slurries to reach equilibrium, the solid
phase was then filtered and analyzed using x-ray powder diffraction (XRPD). The
diffraction data were compared to the simulated powder pattern, HUPPAJ, and
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confirmed that (a) the known IBU-BIPY cocrystal was obtained, (b) an amorphous solid
phase was observed, and (c) the selective cocrystal formation of IBU was achieved. The
comparisons are shown in Figure 3-3, Figure 3-4, and Figure 3-5, respectively.
Figure 3-2 The Structure of 4,4'-bipyridine.
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Figure 3-3 Comparison between the Powder Pattern of the Experimental Solid (Solid
Line) and the Simulated Powder Pattern of the 2:1 IBU-BIPY Cocrystal (Dotted Line).
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Figure 3-4 Comparison between the Powder Pattern of the Experimental Solid (Solid
Line) and the Powder Pattern of KETO (Dotted Line).
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Figure 3-5 Comparison between the Powder Pattern of the Experimental Solid (Solid
Line) and the Powder Pattern of the 2:1 IBU: BIPY Cocrystal (Dotted Line).
Following the same procedure, NCT (Figure 3-6) was found in the CSD to form
a cocrystal with IBU. The cocrystal (refcode: SODDIZ) has a 1:1 stoichiometry
(IBU:NCT). A second search of the CSD found that there is no known cocrystal of
KETO and NCT. We then demonstrated that (a) the known IBU-NCT cocrystal was
obtained, (b) no KETO:NCT cocrystal was formed, and (c) the selective cocrystal
formation of IBU was achieved. The comparisons are shown in Figure 3-7, Figure 3-8,
and Figure 3-9, respectively.
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Figure 3-6 The Structure of NCT.
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Figure 3-7 Comparison between the Powder Pattern of the Experimental Solid (Solid
Line) and the Simulated Powder Pattern of the 1:1 IBU-NCT Cocrystal (Dotted Line).
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Figure 3-8 The Comparison between the Powder Pattern of the Experimental Solid
(Solid Line) and the Powder Pattern of the KETO (Dotted Line).
10000
9000
8000
7000
6000
0 5000
4000
3000
2000
0
5 10 15 20 25 30 35 40
2 Theta
Figure 3-9 The Comparison between the Powder Pattern of the Experimental Solid
(Solid Line) and the Powder Pattern of the 1:1 IBU: NCT cocrystal (Dotted Line).
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To select the optimal solvent for the separation process, we measured the
solubilities of KETO, IBU, and the IBU-BIPY cocrystal in ethyl acetate and in mixtures
of H20/EtOH mixture, at various temperatures following the procedure described in
section 3.2.3.
3.2.3 Solubility measurements
Solubilities were measured using both a Thermofisher Clarity solubility station,
described by Yi et. al.,27 and HPLC. To measure the solubility of the target compound
using HPLC, the compound of interest was added to the proper solvent to make
supersaturated solutions. The slurry was stirred with magnetic stir bars in 20 ml glass
vials overnight at a constant temperature maintained using a circulating water bath to
reach equilibrium. The liquid phase was filtered using 0.45 pm PTFE syringe filters and
diluted using the same solvent as the HPLC mobile phase. The concentration of the
liquid phase was determined using HPLC (detailed method described in section 3.2.6).
The solid phase was collected using vacuum filtration with filter papers and dried at
room temperature overnight. These dried solids were confirmed to be the desired
polymorph, if any, using XRPD.
3.2.4 Separation experiments
Separation experiments were performed in both EtOAc and a 50% H20/EtOH
mixture. The initial solution contained a saturated amount of the target (KETO) at 20"C
and the impurity (IBU) at an equimolar ratio. The amount of coformer added was the
stoichiometric amount to form the cocrystal with the impurity. That is, the impurity to
coformer ratio was the same as the stoichiometry used to make the impurity cocrystal.
The solution was stirred overnight in a water bath at 20 0C. The solids obtained from the
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crystallization were analyzed using XRPD and the compositions of the liquid phase were
determined using the high performance liquid chromatography (HPLC) method
described in 3.2.6.
3.2.5 Phase solubility diagram construction
Different compositions of A and B solids (A-B combinations: IBU-BIPY and
IBU-NCT) were added to a 50% H20/EtOH mixture to make supersaturated solutions
with respect to all components and the cocrystal. The slurries were stirred with magnetic
stir bars in 20 ml glass vials overnight at a constant temperature (20'C) maintained using
a circulating water bath to reach equilibrium. The liquid phase was filtered using 0.45
ptm PTFE syringe filters and diluted using the same solvent as the HPLC mobile phase
(30/70 water/acetonitrile with 0.1% trifluoroacetic acid). The concentration of the liquid
phase was determined using the HPLC method described in section 3.2.6. The solid
phase was collected using vacuum filtration with filter papers and dried at room
temperature overnight. The dried solids were confirmed to be the desired cocrystal using
X-ray powder diffraction.
3.2.6 High-Performance Liquid Chromatography
The HPLC instrument (Agilent 1260 Infinity) was equipped with a UV diode
array detector (Agilent Technologies G1315D). The column used was a YMC-Pack
ODS-A 150x4.6 mm I.D. column packed with 3 jim particles with 12 nm pore size
(YMC America Inc.). The maximum wavelength for absorbance was set at 230 nm. The
concentrations were analyzed using a 5 min isocratic method with a 30/70
water/acetonitrile mobile phase containing 0.1% trifluoroacetic acid.
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3.2.7 X-ray Powder Diffraction
X-ray powder diffraction patterns were obtained using a PANalytical X'Pert PRO
Theta/Theta powder X-ray diffraction system using a monochromatic CuK0 radiation
source with nickel filter (k = 1.5418 A) generated at 45 kV and 40 mA, using an
X'Celerator high-speed detector. The intensities were measured at 2-theta values from 50
to 40' at a continuous scan rate of 50/min. Aluminum sample holders with a zero
background silicon plate were used to carry out the measurements.
3.3 Results and Discussions
3.3.1 Solvent selection
As described in section 3.2.2, BIPY and NCT were found as two potential
coformers. In this project, BIPY was used to demonstrate the strategy designed to select
the optimal coformer and solvent pair and the optimal coformer concentration. NCT was
later investigated as a potentially better coformer.
To find the optimal solvent, the solubilities of KETO, IBU, and the IBU-BIPY
cocrystal were measured in both EtOAc and H20/EtOH mixtures. The solubility of IBU
was reduced by a factor of 8 from 478.64(±0.15) mg/g to 57.62(±0.15) mg/g by forming
the BIPY cocrystal in EtOAc. However, despite the large decrease of IBU solubility, the
IBU concentration was still too high to meet the separation standard. Solubilities of all
components in H20/EtOH mixtures with the concentration varying from 100% water to
50% water were measured (Figure 3-10). Since IBU is sparingly soluble in water and
soluble in ethanol, the desirable IBU solubility can be found by tuning the solvent
composition. The solubility of IBU decreased the most when it formed a cocrystal in the
50% H20/EtOH mixture (Table 3-1). Hence, the 50% water/ethanol mixture was chosen
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to be our solvent. Indeed, the solubility of IBU decreased by a factor of 9 from
54.50(±0.056) mg/g to 5.90(±0.012) mg/g by forming the BIPY cocrystal.
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Figure 3-10 Solubilities of IBU, KETO, BIPY, and the IBU Cocrystal in Different
Solvent (H20/EtOH) Combinations.
Table 3-1 Comparison of IBU Solubility and its Solubility in Cocrystal in Different
Solvent (H20/EtOH) Combinations.
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OIBU solubility
AKETO solublity
OBIPY solubility
8
Oco-crystal solubility
Water Content IBU Solubility IBU Solubility in Cocrystal
(mg/ g solvent) (mg/ g solvent)
100% 0.10+0.016 0.29+0.024
90% 0.10+0.013 0.57±0.082
80% 0.30+0.01 0.71±0.04
70% 1.38+0.023 1.35+0.012
60% 12.65±0.047 1.98+0.042
50% 54.50±0.056 5.90+0.012
40% 175.84+0.038 31.36±0.093
L
3.3.2 Separation experiments
Separation experimental conditions and results are shown in Table 3-2. In these
experiments, a saturated amount of KETO at 200C and IBU at an equimolar ratio was
contained in the initial solution. BIPY was added at a 2:1 ratio to IBU to achieve the
separation. The concentration of IBU, upon cocrystal formation, decreased from
149.10(±0.80) mg/g to 103.87(±1.47) mg/g in EtOAc while it decreased from
68.60(11.20) mg/g to 28.04 (10.23) mg/g in the 50% H20/EtOH mixture. Thus, both the
solubility and separation experiments indicate that the 50% H20/EtOH mixture is a more
effective solvent than EtOAc for the IBU/KETO system.
Table 3-2 Conditions of Separation Experiments.
Solvents Initial Initial Final Final
[KETO] [IBU] [IBU] [BIPY]
(mg/g) (mg/g) (mg/g) (mg/g)
EtOAc 184.8910.37 149.10+0.80 103.8711.47 11.2910.56
50% H20/EtOH 85.34+0.66 68.60+1.20 28.0410.23 4.23+0.14
As shown in the separation experiments, the final IBU concentration is higher
than the IBU concentration indicated by the solubility measurements. This increase was
due to the presence of KETO. The solubility of the cocrystal was measured as a function
of KETO concentration, and the results are shown in Figure 3-11. The effective IBU
concentration increased linearly with increasing KETO concentration, indicating that the
presence of the intermediate can significantly decrease the impurity cocrystal solubility.
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Figure 3-11 The Solubility of the Cocrystal (as Indicated by the Effective IBU
Concentration) as a Function of KETO Concentration.
3.3.3 Phase solubility diagram
To find the lowest IBU concentration that can be obtained by adding the
coformer, we constructed the PSD (Figure 3-12). The lowest IBU concentration
achieved was 3.40(±0.39) mg/g for the 1:1 IBU:BIPY stoichiometry. Importantly, this
result demonstrated that the solution stoichiometry resulting in the lowest impurity
concentration (1:1 IBU:BIPY) does not have to be the same as the stoichiometry of the
cocrystal (2:1 IBU:BIPY in our case).
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Figure 3-12 Phase Solubility Diagram of IBU in the presence of BIPY in the 50%
H20/EtOH Mixture at 200 C and latm.
3.3.4 Other improvements
In the separation experiment, the lowest IBU concentration we could achieve
was 28.04(±0.23) mg/g in a 50% H20/EtOH mixture by forming its cocrystal with
BIPY; however, the final BIPY concentration in solution was 4.23(±0.14) mg/g. To
improve the separation results obtained in the previous experiments, it is necessary to
decrease the effective IBU solubility. Potential methods include the cooling of the
resulting solution from previous separation experiments or by the formation of a
different IBU cocrystal whose solubility is lower than that of the IBU-BIPY cocrystal.
To evaluate the first approach, both the KETO solubility and the effective IBU
solubility in the IBU-BIPY cocrystal at various temperatures were measured. By cooling
the resulting solution from previous separation experiments, both KETO and the IBU-
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BIPY cocrystal crystallize. Although the concentration of IBU decreased in solution, the
yield of KETO decreased as well. Cooling would only be worth pursuing when the
solubility of the cocrystal decreases faster than does the solubility of KETO. Figure 3-13
shows that the solubility of the cocrystal decreases much slower than the solubility of
KETO does with decreasing temperature. Hence, in this case, cooling is not an effective
way to improve the separation results.
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Figure 3-13 KETO Solubility and Effective IBU Solubility in Its Cocrystal at Various
Temperatures.
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To evaluate the second approach, a low solubility coformer, nicotinamide (NCT),
was investigated. However, despite its low solubility compared to BIPY, its cocrystal
with IBU had a higher solubility (lowest at 147.50(±2.30) mg/g solvent according to
Figure 3-14) than that of the IBU-BIPY cocrystal does. Hence, it cannot be used to
improve the separation results.
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Figure 3-14 Effective IBU Solubility in the IBU-NCT Cocrystal at Various NCT
Concentrations in the 50% H20/EtOH Mixture at 200C.
3.3.5 Summary
IBU and KETO were chosen as the model impurity and target, respectively.
BIPY was chosen as the coformer to crystallize IBU from a IBU/KETO mixture
selectively. By measuring the solubilities of all components, we found that a 50%
H20/EtOH mixture is a better solvent than EtOAc. This conclusion was later confirmed
in the separation experiments. The IBU concentration was decreased from 68.60( 1.20)
mg/g to 28.04(±0.23) mg/g in the 50% H20/EtOH mixture, and 4.23(±0.14) mg/g of
BIPY remained in solution. The presence of KETO increased the cocrystal solubility
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from 5.90(±0.012) mg/g to 28.04(±0.23) mg/g. A PSD of IBU and BIPY was constructed
to find that the lowest IBU concentration (3.40(±0.39) mg/g) can be found at a 1:1
IBU:BIPY stoichiometry. Two attempts (a cooling process and the use of NCT as an
alternative coformer) were made to improve the separation result achieved using BIPY
in the 50% H20/EtOH mixture. The cooling process was not adapted because the KETO
solubility decreased much faster than the cocrystal solubility did with decreasing
temperature. NCT was determined to be a less ideal coformer since its cocrystal has a
much higher solubility than the BIPY cocrystal does.
3.4 Conclusions
Using IBU and KETO as our model compounds, we showed that the impurity in
a solution can be removed by its cocrystal formation. A workflow was established to
choose the optimal coformer, concentration of the coformer, and solvent for the specific
impurity/target system. In the separation experiment, the IBU concentration was reduced
to 28.04(±0.23) mg/g in a 50% H20/EtOH mixture by forming its cocrystal with BIPY;
however, the final BIPY concentration in solution was 4.23(±0.14) mg/g. For an
effective separation method, the impurity and coformer concentrations in the final
solution must be reduced to a lower level.
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4. THE PURIFICATION OF STRUCTURALLY SIMILAR
COMPOUNDS BY THE FORMATION OF IMPURITY
COMPLEXES IN SOLUTION
4.1 Introduction
In this approach, we investigated the possibility to purify structurally similar
compounds by the formation of impurity complexes in solution. Two well-studied
systems in the field of tailor-made additives, the benzamide/benzoic acid (BAM/BA)
system and the cinnamamide/cinnamic acid (CAM/CA) system, were chosen as our
model systems. Tailor-made additives are typically designed to alter properties of active
pharmaceutical ingredients (API) such as morphologies. 4 They can also be used as
nucleation promoters and growth inhibitors.28-30 Tailor-made additives are designed (or
selected) to be structurally similar to the API. Because of the structural similarity, it is
easy for a tailor-made additive to substitute into the API crystal lattice and disturb the
growth of the API crystal when the API was crystallized from an API/impurity mixture.
Berkovitch-Yellin et al. used BA to change the morphology of BAM.2 The low impurity
level (reported between 0.5% to 1%) made the BAM/BA system a good system for the
purpose of this work. Similarly, CAM/CA was chosen to be our second system because
of its similarity to the BAM/BA system. The structures of BAM, BA, CAM, and CA are
shown in Figure 4-1. Both systems were investigated for purification.
0 0 NH 2  0
NH2  OH O OH
Figure 4-1 Structures of Benzamide, Benzoic Acid, Cinnamamide, and Cinnamic Acid
(from Left to Right).
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The aim of this work was to prevent the impurity from substituting into the
crystal lattice of the target compound. To achieve this, we added a coformer that could
form a cocrystal with the impurity to the impurity/target mixture. In the 1950s, Higuchi
conducted research on complexes formed in solution by caffeine.3 1-3  The
stoichiometries of these complexes and the mechanisms of complex formation were
studied. It is proven that complexation can affect solid properties. In our work, we
assumed that (1) coformers that could form cocrystals with the impurity have a high
probability of forming complexes with the impurity in solution and (2) because of steric
effects, the impurity complexes would no longer fit into the crystal lattice of the target
compound. By adding coformers, the amount of the impurity incorporated into the
crystal lattice would decrease, thereby purifying the compound of interest.
To confirm that the purification was due to the complexation in solution, we
estimated the binding constants of the complexes and used them as indicators for the
level of complexation. Phase solubility diagrams for cocrystal systems were used to find
the stoichiometry and the binding constants for these complexes in equilibrium with
cocrystals. 10'36 With different combinations of the cocrystal stoichiometry, complex
stoichiometries, and the binding constants of the complexes, the solubility of the
cocrystal is a unique function of the coformer concentration.'' Nehm et al. showed that
when compound A forms a 1:1 cocrystal with coformer B in the absence of complex
formation, the solubility product can be expressed as:7
K,, = [A][B] (4-1)
where Ksp is the solubility product of the AB cocrystal, and [A] and [B] are the
concentrations of both cocrystal components at equilibrium. The solubility product can
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be calculated from the plot of [A] versus . If there is 1:1 complex formation in[B]
solution, the total concentration of A, [A]1, can be expressed as:7
[A]T = KsP + KnK,, (4-2)[B]T-K11KSp
where [B]T is the total concentration of B and K 1 is the binding constant of the 1:1 AB
complex. Assuming KlKsP<<[B]T, the total concentration of A, [A]T, can be expressed
7
as:
[A]T = sp + KKsP (4-3)
Similarly, if A and B form a 2:1 cocrystal, the solubility of this binary cocrystal
A2B in a pure solvent where the cocrystal components do not ionize or form complexes
in solution is given by the equilibrium reaction:
A2BsOlid Is 2 sointion + Bso lu t io n  (4- 4)
The equilibrium constant for this reaction is given by:
KSP = aA2aB (4- 5)
aA2 B
Assuming that the activity of the solid and the activity coefficients are 1, the cocrystal
solubility product can be expressed as:
Ksp ~ [A] 2 [B] (4-6)
Therefore, if the A2B cocrystal is dissolved in pure solvent and there is no further
ionization or complex formation in solution, then the plot of [A]T 2 against I would be[B]T
linear with a slope of Ksp.
If a 1:1 complex forms in solution, the equilibrium reactions become:
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A2Bsoid 2As oition + Bsolution (4- 4)
Asolution + Bsolution 1 ABsolution (4- 7)
The solubility product remains the same as that given in Eq. (4-6) and the binding
constant for the 1:1 complex can be expressed as:
K11 = [AB] (4-8)[A] [B]
The mass balances of A and B in solution are:
[AlT = [A] + [AB] (4-9)
[B]T = [B] + [AB] (4-10)
If a 2:1 complex forms in solution, the equilibrium reactions are:
A2Bsolid 2Asointion + Bsolution (4-4)
2Asolution + Bsolution - AzB5 Olution (4-11)
The equilibrium constants are expressed as Eq. (4-6) and as:
K2 1 = [A2 B] (4-12)[AB][A]
The mass balances of A and B are:
[A]T = [A] + 2[A2B] (4-13)
[B]T = [B] + [A2B] (4-14)
If both the 1:1 and the 2:1 complexes are formed in solution, then the
equilibrium reactions are:
A 2 BsOit 2IA- solution + Bsolution (4-4)
Asolution + Bsolution - ABsOlution (4-7)
ABsolution + Asolution AzBSOlution (4-15)
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The equilibrium constants are expressed as Eq. (4-6), Eq. (4-8), and (4-12).
The mass balances of A and B are now:
[A]T = [A] + [AB] + 2[A2 B] (4-16)
[B]T = [B] + [AB] + [A2B] (4-17)
In the case where A and B form 2:1 cocrystals, the binding constants cannot be
solved analytically. Instead, they can be fitted using [A]T and [B]T obtained
experimentally. Phase solubility diagram data measured for a cocrystal system with a
known cocrystal stoichiometry can be used to determine if the cocrystal components
form complexes in solution as well as the binding constants of the complexes.
The following coformers were chosen to form complexes with the impurities, BA
and CA: (1) isonicotinamide (INA), (2) 2-amino-4,6-dimethylpyrimidine (DMP), and
(3) dimethylglyoxime (DMG). Separation experiments were performed and the purities
of the target compounds, BAM and CAM, under different experimental conditions were
measured. The results are presented in Table 4-2, Table 4-3, and Table 4-4, respectively.
Two systems showed promising purification results: (1) BA-DMG and (2) CA-DMP.
Phase solubility diagram data for these two systems were measured and used to find the
binding constants of the complexes formed in solution. Phase solubility diagram data for
other two systems that did not show significant purification were measured as
comparisons. The purification results were explained using the level of complexation in
solution.
In this work, we were able to purify BAM and CAM by adding coformers
reported to form cocrystals with the impurities, BA and CA, respectively. These
coformers were confirmed to form complexes with the impurities and hence prevent the
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impurities from substituting into the crystal lattice. These findings have practical
applications in the development of purification methods.
4.2 Materials and Methods
4.2.1 Materials
Benzoic acid (BA, ACS reagent, > 99.5%), benzamide (BAM, 99%), trans-
Cinnamic acid (CA, > 99%), cinnamamide (CAM, predominately trans, 97%), 2-amino-
4,6-dimethylpyrimidine (DMP), dimethylglyoxime (DMG, ACS reagent) and
isonicotinamide (INA, lot no. BCBD6627V, 99%) were purchased from Sigma-Aldrich
and were used as received. Anhydrous ethanol (200 proof) was USP grade and was
purchased from VWR. Methanol (MeOH, CHROMASOLV* for HPLC >99%) and
water (H20, CHROMASOLV* Plus for HPLC) were purchased from Sigma-Aldrich and
used for HPLC.
4.2.2 Coformer selection
A search in CSD was conducted to select the coformers reported to form
cocrystals with the impurities, BA and CA. This search led to the selection of three
coformers: (1) isonicotinamide (INA), (2) 2-amino-4,6-dimethylpyrimidine (DMP), and
(3) dimethylglyoxime (DMG). Their structures are shown in Figure 4-2. The reference
codes of these reported cocrystals in CSD are presented in Table 4-1.
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(a) (b)
CH3
HO N OH
CH3
(c)
Figure 4-2 Structures of (a) Isonicotinamide (INA), (b) 2-amino-4,6-dimethylpyrimidine
(DMP), and (c) dimethylglyoxime (DMG).
Table 4-1 Reference Codes of the Reported Cocrystals.
These six cocrystals were made successfully. Four cocrystals (BA-INA, BA-
DMP, CA-INA, and CA-DMP) were prepared using solution crystallization with the
reported cocrystal stoichiometry (1:1 molar ratio). BA-DMG and CA-DMG cocrystals
were prepared using a different stoichiometry (1:1 molar ratio) from the cocrystal
stoichiometry (2:1 molar ratio) because of the low solubility of DMG in ethanol. The
obtained cocrystals were confirmed to be the reported ones using X-ray powder
diffraction (XRPD).
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INA DMP DMG
BA BUDWEC VOCZET, NABCAV,
VOCZETO1, NABCAVO1
VOCZET02,
VOCZET03
CA LUNMAI DAYWAC NABCEZ
4.2.3 Crystallization experiments
Three sets of experiments were performed to determine if the coformer could be
used to purify the target compound. In the first experiment, BAM and CAM were
crystallized with coformers to determine if the coformers substitute into their crystal
lattices. The coformers incorporated into the target crystal lattices were no longer
investigated further. In the second experiment, BAM and CAM were crystallized with
only the impurities, BA and CA, respectively, to examine how much impurity was
incorporated into the target crystal lattices. In the third experiment, BAM and CAM
were crystallized with both the impurity and the coformers that were not excluded after
the first experiment to examine the purities of BAM and CAM after the addition of
coformers. The initial solution contained the saturation concentration of the target
compound at 400C and the impurity at weight ratios of 1:9 and 1:4 to the target
compound. The amount of coformer added was the stoichiometric amount to form the
cocrystal with the impurity. That is, the impurity to coformer ratio was the same as the
stoichiometry used to make the impurity cocrystal. The solution was heated in a water
bath to 50"C until the target compound dissolved. The solution was cooled to 30'C at a
rate of 1"C/min and then to 200C at a rate of 10C/6 min. The solids obtained from the
crystallization were collected and washed using iced ethanol. The purities of the
resulting products were determined using high performance liquid chromatography
(HPLC).
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4.2.4 Phase solubility diagram construction
The same procedure as described in section 3.2.5 was followed. Different
compositions of A and B solids (A-B combinations: BA-DMP, BA-DMG, CA-DMP,
CA-INA) were added to ethanol to construct phase solubility diagrams.
4.2.5 High Performance Liquid Chromatography (HPLC)
The same HPLC instrument and column as those described in section 3.2.6 were
used. The maximum wavelength for absorbance was set at 230 nm. The concentrations
were analyzed using a 5 min isocratic method with a 30/70 water/methanol mobile phase
containing 0.1% trifluoroacetic acid.
4.2.6 Model fitting
Different approaches were used to calculate the binding constants of the
complexes for the cocrystal systems. For each 1:1 cocrystal system, the plot of the total
impurity concentration versus the reciprocal of the total coformer concentration was
analyzed using least squares regression. If linear dependence was shown, we could find
the solubility product, Ksp from the slope and the binding constant for the 1:1 complex,
K,1 , from the intercept. An intercept that was not significantly different from 0 indicated
that there was no complexation and that K11 was 0. Otherwise, the binding constants of
the complexes, K11, could be determined using Eq. (4-3). If no linear dependence was
shown, then Eq. (4-2) was used to find the solubility product and the binding constant of
the complex. Eq. (4-2) can be rearranged and expressed as:
([A]Tx[B]T) = KnKsp([A]T + [BIT) + (Ksp - K112KSP 2 ) (4-18)
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The plot of ([AlT x[B]T) versus ([A]T + [B]T) was thus used to find the
solubility product and the binding constant using Eq. (4-19) and (4-20).
Ksp = intercept + slope2  (4-19)
K1 slope (4-20)
Ksp
For the 2:1 cocrystal system, the solubility product and binding constants could
not be found using linear regression. Instead, the phase solubility diagram data obtained
for the BA-DMG system was fitted to four different models: the 2:1 cocrystal system
with no complexation, the system with the 1:1 complex in solution, the system with the
2:1 complex in solution, and the system with both 1:1 and 2:1 complexes, respectively.
In the first model, the cocrystal components do not ionize or form complexes in solution.
For a given Ksp, the total concentrations of A, [A]T, fitted, were calculated using Eq. (4-6)
and the experimentally measured concentrations of B. [A]T, fitted, were then compared to
the total concentrations of A obtained experimentally, [A]T, exp. The method of least
squares was applied to find the best solution, or the solution with the minimum sum of
squared errors, which was defined as:
Sum of Squared Errors = 2([A] T,exp - [A] T itted )2 (4- 21)
Various Ksp values (from 0 to 10 in steps of 0.0001) were examined to find the
best Ksp value that minimized the sum of squared errors. This range was chosen based
on the estimation using Eq. (4-6) and the fact that it should be >0.
The second, third and forth models were fitted in the same way. In the second
model, the 2:1 cocrystal is in equilibrium with the 1:1 complex in solution. Given Ksp
and K,1 , [A]T, fitted were calculated using Eq. (4-6), (4-8), (4-9), and (4-10) and [B]T, exp.
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Various values of Ksp (from 0 to 10 in steps of 0.0001) and K,1 (from 0 to 100 in steps of
0.0001) were examined to find the optimal ones that minimized the sum of squared
errors defined in Eq. (4-21). The range for K 1 was chosen based on literature values and
the fact that it should be >0. In the third system where only the 2:1 complex is in
equilibrium with the 2:1 cocrystal, we calculated [A]T,fitted using Eq. (4-6), (4-12), (4-13),
(14), and [B]Texp. Various values of Ksp (from 0 to 10 in steps of 0.00001) and K21 (from
0 to 100 in steps of 0.0001) were examined to find the optimal ones that minimized the
sum of squared errors defined in Eq. (4-21). The range for K2 1 was chosen based on
literature values and the fact that it should be >0. Similarly, in the fourth system where
the 2:1 cocrystal is in equilibrium with both 1:1 and 2:1 complexes, we calculated [A]T,
fitted using Eq. (4-6), (4-8), (4-12), (4-16), (4-17), and [B]T, exp. Ksp, K,, and K2 1 values
that give the minimum sum of squared error were found after various Ksp values (from 0
to 10 in steps of 0.0001), K 1 values (from 0 to 100 in steps of 0.0001), and K 21 values
(from 0 to 100 in steps of 0.0001) were tested, respectively. A Matlab program was
written to perform the method of least squares on the four models.
4.3 Results and Discussions
4.3.1 Purification results
The purities of BAM obtained from the crystallization experiments are presented
in Table 4-2. The results using INA are not shown in the table because it substituted into
the BAM crystal lattice and therefore was not used to purify BAM. The original mass
percentage of BA in the BAM crystal was 0.3 5(±0.033) wt%. Once DMP was added (1:1
molar ratio of BA:DMP), the amount of BA in the BAM crystal decreased to
0.32(±0.049) wt% with 0.087(±0.02) wt% of DMP present in the BAM crystals. With
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the addition of DMG (1:1 molar ratio of BA:DMG), the amount of BA in the BAM
crystals decreased to 0.28(±0.025) wt% with no trace of DMG detected. The effect of
the coformer stoichiometry was studied by varying the amount of DMG (1:1.5 and 1:2
molar ratios of BA:DMG). With the addition of 1:1.5 and 1:2 molar ratios of DMG, the
amount of BA decreased to 0.32(±0.024) wt% and 0.31(±0.029) wt%, respectively. To
determine whether the decreases are statistically significant at a 95% confidence
interval, all of the amounts of BA after the addition of coformers were compared to the
original amount of BA using a t-test. The decreases of the amount of BA after the
addition of DMG at all molar ratios were determined to be statistically significant
(p=0.00005359 for the 1:1 molar ratio, p=0.04717 for the 1:1.5 molar ratio, and
p=0.0 1899 for the 1:2 molar ratio). On the other hand, the decrease of the amount of BA
after the addition of DMP was not statistically significant (p=0.1204). In addition, a t-
test was performed to determine whether the amount of BA decreases with an increasing
amount of DMG added. The amounts of BA with the addition of 1:1.5 and 1:2 molar
ratios of DMG were compared to that with the addition of a 1:1 molar ratio of DMG,
respectively. The results showed that increasing the amount of DMG did not statistically
significant decrease the amount of BA substituted into the crystal lattice (p=0.9908 for
1:1.5 molar ratio and p=0. 96 9 4 for the 1:2 molar ratio).
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Table 4-2 Purities of Benzamide in Different Crystallization Experiments.
(The Initial Solution contained a 9:1 Weight Ratio of BAM:BA.)
BA DMP DMG Decreased
(wt%) (wt%) (wt%) (%)
BAM/BA 0.35±0.033 -
With DMP 0.32±0.049 0.087±0.020 - 8.18
With Ix DMG 0.28±0.025 - 0.00 18.79
With 1.5x DMG 0.32±0.024 - 0.00 7.71
With 2x DMG 0.31±0.029 - 0.00 11.00
The purities of CAM obtained from the crystallization experiments are shown in
Table 4-3. The original mass percentage of CA in CAM crystal was 0.85(±0.078) wt%.
Once DMP was added (1:1 molar ratio of CA:DMP), the amount of CA in CAM crystal
decreased to 0.65(±0.101) wt%. After the addition of INA (1:1 molar ratio of CA:INA),
the amount of CA decreased to 0.76(±0.142) wt%. However, the addition of DMG
increased the amount of CA incorporated into CAM crystal lattices to 0.92(±0.153) wt%.
No trace of coformers was detected in any resulting CAM solids. A t-test determined
that the amount of CA that decreased with the addition of coformers was statistically
significantly at a 95% confidence interval. The amounts of CA decreased statistically
significantly with the addition of DMP (p=0.009485) but not significantly with the
addition of DMG (p=0.7684) and INA (p=O.147 1).
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Table 4-3 Purities of Cinnamamide in Different Crystallization Experiments.
(The Initial Solution Contained a 9:1 Weight Ratio of BAM:BA.)
CA Decreased
(wt%) (%)
CAM/CA 0.85±0.078
With DMP 0.65±0.101 23.79
With DMG 0.9240.153 -7.88
With INA 0.76±0.142 10.93
The effect of the initial impurity concentration was investigated using the
CAM/CA system. CA was added at a weight ratio of 1:4 to CAM. DMP (1:1 molar ratio
of CA:DMP) was added to purify CAM crystals. The purities of CAM obtained from the
crystallization experiments are shown in Table 4-4. The original mass percentage of CA
in the CAM crystals was 2.01(±0.21) wt%. Once DMP was added (1:1 molar ratio of
CA:DMP), the amount of CA in the CAM crystals decreased to 1.58(±0.20) wt%. No
trace of DMP was detected in any resulting CAM solids. A t-test determined that the
amount of CA decreased with the addition of coformers statistically significantly at a
95% confidence interval (p=0.03045).
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Table 4-4 Purities of Cinnamamide in Different Crystallization Experiments.
(The Initial Solution Contained a 4:1 Weight Ratio of BAM:BA.)
CA Decreased
(%) (%)
CAM/CA 2.010.21
WITH DMP 1.58±0.20 21.56
To summarize, two systems showed statistically significant increases of the
purities of the compounds of interest: the BA-DMG system and the CA-DMP system.
The addition of other coformers did not have a significant effect on the amount of
impurities incorporated into the crystal lattices of the target compounds. In the BA-
DMG system, the amount of BA did not decrease with an increasing amount of DMG
added.
4.3.2 Complexation measurement
To examine whether the level of complexation has a correlation to the
purification results, we estimated the binding constants of the complexes in our systems
of interest. For the BAM/BA system, DMG was an effective coformer for BAM
purification. Since BA and DMG are known to form a 2:1 cocrystal, the stoichiometries
and the binding constants of complexes were determined using the method described
above for 2:1 cocrystals. Model 3 had a large error (0.4393) compared to other models
(0.0065 for model 1 and 0.018 for model 2 and 4) and was not considered. The facts that
K21 was determined to be 0 in model 4 and that the values of Ksp and K 1 were identical
in model 2 and 4 (Ksp=0.4413 and Kli=0.3469) indicated that the assumption of having a
2:1 complex did not change the behavior of model 2. That is, no 2:1 complex was
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present in solution and model 4 was not considered. Model 1 had a smaller sum of
square error than model 2 did. However, it is highly unlikely to form 2:1 cocrystals
without complex formation in solution. Therefore, model 2 was the reasonable model
that fitted best to the experimental data.
The BA-DMP system was also examined for complexation behavior. BA and
DMP are known to form a 1:1 cocrystal. Following the method described above for
systems forming 1:1 cocrystals, the total impurity concentrations (BA) were plotted
against the reciprocal of the total coformer concentrations (DMP). Linear regression
with least squares was applied and no linear dependency was shown (R2=0.84234).
Linear regression was again applied using Eq. (4-18). The results are shown in Figure
4-3. The solubility products and the binding constants were calculated using Eq. (4-19)
and (4-20) with the slope and the intercept obtained from Figure 4-3. The solubility
product was 0.0053 and the binding constant for the 1:1 complex was 6.67.
0.04 y = 0.0354x + 0.0041
0.035 -R2= 0.93914
0.03
0.025
0.02
0.015
6-- 0.01
0.005
0 --
0 0.2 0.4 0.6 0.8 1
[BA]+[DMP] (M)
Figure 4-3 Linear Regression Results of the BA-DMP System.
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For the CAM/CA system, the addition of DMP significantly decreased the
amount of CA incorporated into CAM crystal lattices. CA and DMP are known to form
1:1 cocrystals and Eq. (4-1) was used to perform linear regression and no linear
dependence was shown (R2=0.25146). Linear regression was applied using Eq. (4-2) and
the results are presented in Figure 4-4. Ksp (0.0018) and K11 (64.86) were calculated
using Eq. (4-19) and (4-20).
0.25
y 0.1166x - 0.0118 0
0.2 R
2
= 0.99345
0. 1
U
0.05
0
0 0.5 1 1.5 2
[CA]+[DMP] (M)
Figure 4-4 Linear Regression Results of the CA-DMP System.
The complexation behavior in the CA-INA system was examined as a
comparison to that in the CA-DMP system. Linear regression using Eq. (4-1) was
performed because CA forms 1:1 cocrystals with INA. A linear dependence was shown
in Figure 4-5 (R2=0.98). Examination of the linear regression analysis revealed that the
y-intercept was not statistically different from zero (p=0.762). This fact suggested that
no complex was formed in solution. Based on Eq. (4-1), the solubility product of the
CA-INA system was the slope of the regression line, 0.023. The solubility products and
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the binding constants for the 1:1 complex for the BA-DMG, BA-DMP, CA-DMP, and
CA-INA systems are summarized in Table 4-5.
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Figure 4-5 Total CA Concentration in Equilibrium with the Cocrystal, CA-INA, as a
Function of the Reciprocal of Total INA Concentration in Ethanol at 200C.
Table 4-5 Solubility Products and Binding Constants for (1) BA-DMG, (2) BA-DMP,
(3) CA-DMP, and (4) CA-INA.
BA-DMG BA-DMP CA-DMP CA-INA
Ksp 0.4413 0.0053 0.0018 0.023
Ki1  0.3469 6.67 64.86 0
4.3.3 Discussions
Results for the BAM/BA system did not show a positive correlation between the
complexation level in solution and the purification results. The addition of DMG
decreased the amount of BA the most but the binding constant of the BA-DMG complex
was smaller than that of the BA-DMP complex. This result can be explained by the fact
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0 0
y = 0.0231x - 0.0018
R2= 0.98223
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that DMP substituted into BAM crystal lattices. As shown in Table 4-2, after the addition
of DMP, DMP was detected in CAM crystals (0.087(±0.020) wt%). It is likely that some
BA-DMP complexes substituted into BAM crystal lattices. Therefore, despite the high
complexation level in the BA-DMP system, the purity of BAM was enhanced the most
with the addition of DMG.
A positive correlation was found between the level of complexation in solution
and purification results in the CAM/CA system. The amount of CA decreased the most
with the addition of DMP. On the other hand, the addition of INA did not decrease the
amount of CA significantly. In addition, the binding constant of the CA-DMP complex
was much larger than that of the CA-INA complex. We can conclude that for the
CAM/CA system, the more complexes formed in solution, the better the purification
results are.
This positive correlation was observed when we compared the results of the two
systems that showed significant decreases: the BAM/BA system with the addition of
DMG and the CAM/CA system with the addition of DMP. Although the original
impurity levels were different in the BAM/BA and CAM/CA systems, we can compare
purification results by calculating the decreases of impurity amounts in moles/g solids.
The decrease of the CAM-CA-DMP system was 1.3x100 moles/g solids while the
decrease of the BAM-BA-DMG system was 5.3x10-6 moles/g solids. The binding
constant of CA-DMP complex was significantly larger than that of the BA-DMG
complex. The level of complexation can be used to explain purification results in
different API/impurity systems.
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The complexation in purification experiments was not measurable using
spectroscopy methods (including raman spectroscopy, ultraviolet-visible spectroscopy,
and infrared spectroscopy) and nuclear magnetic resonance (NMR). For spectroscopy
methods, impurity peaks overlap with coformer peaks and it is difficult to identify the
contribution from the impurity, the coformer, and their complex. For NMR
measurements, the complexation was not observed due to the concentration limit
allowed in NMR. Additionally, the solvent we used in purification experiments, ethanol,
is a polar solvent that can interfere with hydrogen bond formation between the impurity
and the coformer. Hence, binding constants were the best indicators for the level of
complexation in solution even if we only considered the interaction between the
impurity and the coformer.
4.3.4 Summary
BAM/BA and CAM/CA were chosen as our model systems. A search in the CSD
led to the selection of INA, DMP, and DMG as coformers. For the BAM/BA system, the
addition of DMG decreased the amount of BA in the BAM crystal from 0.35(+O.033)
wt% to 0.28(±0.025) wt%. The amount of BA did not decrease with an increasing
amount of DMG added. For the CAM/CA system, the addition of DMP decreased the
amount of CA incorporated into CAM crystal lattices from 0.85(±0.078) wt% to
0.65(±0.101) wt%. We estimated the binding constants in four systems: BA-DMG, BA-
DMP, CA-DMP, and CA-INA to indicate the complexation level in solution. However,
the decrease of the impurity level cannot be solely explained by the amount of impurity-
coformer complexes formed in solution. It is premature to use the complexation
behavior as a predictive tool to select a coformer for purification purposes.
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4.4 Conclusions
In this project, we presented the purification results and complexation behaviors
of the BA/BAM system and CA/CAM system after adding coformers. The results
demonstrated the possibility of purifying structurally similar compounds by adding
coformers to their solutions. The addition of DMG significantly decreased the amount of
BA in BAM crystals. The purity of CAM also increased significantly after the addition
of DMP. While the purification can be explained by the impurity-coformer complex
formation in solution, the addition of coformers has other effects that prevent impurities
from substituting into crystal lattices of the target compound.
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5. THE PURIFICATION OF AMOXICILLIN
5.1 Introduction
In Chapter 4, we investigated the possibility of purifying structurally similar
compounds using selective impurity complex formation in solution followed by
crystallization of the target compound. We postulated that coformers that can form
cocrystals with the impurity are more likely to form complexes with the impurity in
solution and thus the impurity complex is too bulky to fit into the crystal lattice of the
target crystal. Therefore, by adding coformers that can form cocrystals with the impurity
but not with the target to mixtures of the target and impurity, we could prevent
impurities from substituting into the target crystal lattice. For the two systems we studied
(benzamide/benzoic acid and cinnamamide/cinnamic acid), we had knowledge of the
impurity cocrystal formation in advance and were able to demonstrate the potential
feasibility of purifying mixtures of structurally similar compounds by adding coformers
to their solutions. The correlation between the level of complexation and the
purification, however, needs additional experimental verification. In this chapter, a real
drug/impurity system, amoxicillin trihydrate/4-hydroxyphenylglycine (AMCT/4HPG)
was chosen to evaluate the practical use of the proposed method and its mechanism
further.
Amoxicillin trihydrate (AMCT) is one of the major p-lactam antibiotics, which
are widely used against a broad spectrum of bacteria. AMCT has a high solubility, high
absorption rates and high stability under acidic conditions.37 ,38 39 In addition, at the same
dosage, the blood level of AMCT is twice as high as that of ampicillin.40 It was first
brought to the market in 1972 in the trihydrate form. Amoxicillin-clavulanate was later
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introduced as a combination antibiotic as the clavulanate enhances the potency of
amoxicillin.40-
42
Like other p-lactam antibiotics, AMCT was originally produced by a
semisynthetic route. The first generation of the AMCT industrial process was based on
the Dane salt route (Figure 5-1), whose yield could go above 90%. However, the
reaction demands low temperature (-30"C), protection, deprotection and activation steps
and the usage of several undesirable reagents and solvents (e.g. CH 2Cl 2). Consequently,
the amount of waste generated from this process is substantial. 4
H COOMe 0
Me NH H2N>
O + Me C
OK N Me INEt3ICHC] 2I-300C Amoxicillin trihydrate
HO O COOH 2) H+/H 2 0
Figure 5-1 The Industrial Process for AMCT (the Dane Salt Route).
With increasingly tight environmental regulations, the need to replace the Dane
Salt route with an enzymatic synthesis has increased. The enzymatic process takes fewer
steps than the chemical synthetic route does and can be completed in aqueous solutions,
at neutral pH, and at ambient temperature. Two approaches to produce p-lactam
antibiotics have been studied: the thermodynamically controlled approach and the
kinetically controlled approach. Figure 5-2 is the comparison of these two approaches in
penicillin synthesis. In the thermodynamically controlled approach, the side chain reacts
with 6-aminopenicianic acid (6-APA), with penicillin G Acylase (PGA) as the catalyst,
to form the antibiotic, with water as a side product. The main limitation of this approach
is that both the carboxylic acid group on the side chain and the amine group on 6-APA
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need to be neutral for the reaction to occur. However, under the active pH range of PGA,
only few side chains meet this criterion. Attempts were made to overcome this limitation
(different enzymes and different solvents). However, as of today, the kinetically
controlled approach is the main interest and most promising replacement for the
chemical synthetic route. In the kinetically controlled approach, the side chain derivative
reacts with 6-APA to form the antibiotic, with PGA as the catalyst. However, since PGA
can be both a transferase and a hydrolase, it hydrolyzes the side chain derivative and the
product, the antibiotic, while catalyzing the main reaction. Many studies have been
performed to optimize the reaction conditions for the maximum yield, selectivity
(synthesis-to-hydrolysis ratio), and productivity. 40,43
0H,N S C, PGA0
oi OH,) : Synthesis - 1 RjO H, + ,
R HN3 dyS R 1 ~ N+ H20
_< H, Hydtolysis H N H3
0 COOH COOH
(a)
0H2N S CH PGA0
R1 +H Synthesis R 1 "'N + R HR+ 0 2
O COOH COOH
Hydrolysis I PGA+H2O Hydrolysis II PGA+H2O
R , + R 2HH + N H
OH 0CO
(b)
Figure 5-2 (a) Thermodynamically Controlled and (2) Kinetically Controlled Synthesis
of Semi-synthetic Penicillins with PGA as the Catalyst.
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The kinetically controlled synthesis of AMCT is presented in Figure 5-3. This
synthesis has become commercially feasible as the cost of suitable enzymes in robust
and immobilized forms decreases. 40 In this synthesis, 4-hydroxyphenylglycine methyl
ester (HPGM) reacts with 6-APA to produce AMCT. Two hydrolysis reactions occur at
the same time. In the first hydrolysis, the reactant, HPGM is hydrolyzed by PGA in the
presence of water to form 4-hydroxyphenylglycine (4HPG) and methanol. In the second
hydrolysis, the product, AMCT, is hydrolyzed by PGA in the presence of water to form
4HPG and 6-APA. Many studies have been done on the enzymatic synthesis of AMCT
to maximize the yield, selectivity, and productivity. Various studies have been done on
the effects of reactant concentrations, enzyme concentrations, the enzyme inhibitor and
temperatures.44'43'45 Despite all efforts to try to remove it, 4HPG is inevitably present as
an impurity in the synthesis of AMCT.
0 H2N
/\ H11 OH3  PGA
HO - -OCH 3 + -CH PGA. Amoxicillin + CH 30H
NH2  O COOH
4-hydroxyphenylglycine methyl ester 6-aminopenicianic acid
Hydrolysis I PGA+H 2 0 Hydrolysis 
II PGA+H 2 0
H2N
HO -- C-OH + CH 30H HO- -OH +
I "1 2 N _ CH3
NH2  2  0 COOH
4-hydroxyphenylglycine 4-hydroxyphenylglycine 6-aminopenicilanic acid
Figure 5-3 Enzymatic Synthesis of Amoxicillin using PGA as the Catalyst.
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The importance of separating AMCT from its degradation products has been
46addressed in the literature. It has been shown that the degradation products can inhibit
the nucleation process of AMCT, which is similar to the negative influence of impurities
on the nucleation and growth rate in ampicillin crystallization.46,47 Factors affecting the
amount of impurities incorporated into AMCT crystal lattice were also studied. The pH
of the AMCT crystallization process can change the amount of 4HPG incorporated into
AMCT crystal lattices. As the process pH increases, the solubility of 4HPG
increases ,and the powder pH of AMCT increases. Therefore, the amount of 4HPG in
AMCT decreases as the process pH increases. 39 The other factor studied was the
presence of degradation products in the AMCT crystallization process. It was shown that
the purities of AMCT crystallized with the presence of degradation products, whether at
high or low concentration, were at least as pure as the standard material. 46 It is known
that USP grade AMCT should contain no more than 1% of D-hydroxyphenylglycine.
When AMCT was synthesized through the Dane salt route, crystallization was used to
purify and obtain the final products. As the interest in enzymatic synthesis grows, it is
necessary to develop other purification methods, since different amounts of 4HPG can
be incorporated into AMCT in different synthetic routes. Many chromatographic
methods were developed to separate AMCT from 4HPG.4 4'4 6'48-50 However, in industrial
processes, chromatography is often not desirable due to its high cost. Multi-stage
recrystallization is often used to enhance the purity of the product but the yield can be
sacrificed in the process. It is important to develop a separation method to separate
AMCT from 4HPG without sacrificing the yield.
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The goal of this work is to prevent 4HPG from substituting into the crystal lattice
of AMCT by forming 4HPG complexes in solution. Without advance knowledge of
cocrystal formation of 4HPG, a workflow was established to select the optimal coformer
and the optimal amount coformer needed to achieve the best purification. Compounds
with functional groups that could form hydrogen bonds with functional groups on 4HPG
were ground with 4HPG and AMCT to find coformers that could form cocrystals with
4HPG but not with AMCT. We determined if the cocrystal was successfully formed by
comparing the powder pattern of the resulting solid to that of the individual components.
Eleven coformers were found to meet this criterion. AMCT was crystallized with both
4HPG and these coformers and the purities of the resulting products were evaluated
using HPLC. The results are presented in Table 5-7. The four coformers that decreased
the amount of incorporated 4HPG the most were 2-picolinic acid, L-lysine, L-leucine,
and L-isoleucine. The amount of these coformer added was varied to (1) find the optimal
amount of coformer that achieved the best purification, and (2) examine the correlation
between the level of complexation and the purification results. The results are shown in
Figure 5-6.
In this work, we were able to purify AMCT by adding coformers that would form
cocrystals with 4HPG. Better purification was achieved using our proposed method than
two crystallizations from the initial solution. A clear correlation between purification
results and the amount of complexes formed was observed.
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5.2 Materials and Methods
5.2.1 Materials
Amoxicillin trihydrate (AMCT) was purchased from Alfa Aesar and used as
received. 4-hydroxyphenylglycine (4HPG, >98%), and all coformers (Table 5-1, Table
5-2, and Table 5-3) were purchased from Sigma-Aldrich and used as received.
Hydrochloric acid concentrate (to produce a liter of 1.OM HCl) was purchased from
Sigma-Aldrich and measured into a 1 L volumetric flask, which was then filled with
HPLC grade water to the mark. Sodium hydroxide was purchased from Sigma-Aldrich
and used to prepare a 5.OM solution. Potassium phosphate monobasic (for HPLC,
>99.5%) and dibasic (for HPLC, >99.0%) were purchased from Sigma-Aldrich. Water
(H20, CHROMASOLV* Plus for HPLC), methanol (MeOH, CHROMASOLV* for
HPLC >99%) and acetonitrile (ACN, CHROMASOLV* for HPLC >99%) were
purchased from Sigma-Aldrich and used as received.
5.2.2 Coformer selection
To find compounds with the potential to form cocrystals with 4HPG, we needed
to find synthons in which one functional group could interact with a functional group on
4HPG (the carboxylic acid group or the amine group). Forty-seven compounds were
chosen for screening based on this criterion. The entire list can be found in Table 5-1,
Table 5-2, and Table 5-3. These compounds can be categorized as compounds with
functional groups encouraging the formation of synthons with the carboxylic acid group
on 4HPG (Group I, with amide, primary, secondary, and tertiary amine groups, Table 5-
1), the amine group on 4HPG (Group II, with carboxylic acid group, Table 5-2), and
both groups on 4HPG (Group III, with both carboxylic acid and amine group, Table 5-
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3). Solid-state grinding was performed to select coformers that could form cocrystals
with 4HPG but not with AMCT. We ground a 1:1 4HPG:coformer mixture using a
mortar and pestle with few drops of water and measured the powder pattern of the
resulting solid using x-ray powder diffraction (XRPD). The powder pattern was then
compared to the powder patterns of the individual components. If new peaks were
observed, the coformer was then selected to continue to the next step. Powder patterns of
the thirteen resulting solids that show new peaks can be found in Appendix I. Two of
them (4HPG ground with Lysine and Urea at a 1:1 molar ratio, respectively) are shown
as examples in Figure 5-4 and Figure 5-5. In the following step, the coformer was
ground with AMCT at a 1:1 molar ratio. Eleven compounds were found to have the
potential to form cocrystals with 4HPG but not with AMCT (Table 5-4).
88
Table 5-1 Compounds with Amide, Primary, Secondary, and Tertiary Amine Groups
(Group I).
Name Molecular StructureWeight
0
1,3-diethylruea 116.16 )
H H
1,1-diethylurea 116.16 N NH2
0
Urea 60.56 
H2N NH2
4-benzyloxy-2(1H)- 201.22 0 0pyridone
HN
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Table 5-1 Compounds with Amide, Primary, Secondary, and Tertiary Amine Groups
(Group I) (Cont'd)
Name Molecular StructureWeight
F
F
6-methyl-4- F
(trifluoromethyl)-2(l H)- 177.12
pyridone NH
H
N 0
5-bromo-2(1 H)-pyridone 
174 BBrI
N OH
2-hydroxypyridine 95.1
H
N
0
2-imidazolidone 86.09
CNH
0 0
3-nitrobenzamide 166.13 -oN NH2
0
4-chlorobenzamide 155.58 NH2
Ci
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Table 5-1 Compounds with Amide, Primary, Secondary, and Tertiary Amine Groups
(Group I) (Cont'd).
Name Molecular StructureWeight
o 0II
-O N+ NH 2
3,5-dinitrobenzamide 211.13
0
-
HNN
Theobromine 180.16 O)
o N N
Carbamazepine 236.27 N
NH2
0
Acetamide 59.07
NH2
N-phenylurea 136.15
N KNH 2
H
HNIdo60
Imidazole 68.08 N
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Table 5-1 Compounds with Amide, Primary, Secondary, and Tertiary Amine Groups
(Group I) (Cont'd).
Name Molecular StructureWeight
0 0
Malonamide 102.09 H2 N H2
H O OH
4,6-dihydroxypyrimidine 112.09
N N
NH
Benzamidine 120.15 NH2
N
1,2-bis(4-pyridyl)ethane 184.24
N(
N
1,2-di(4-pyridyl)ethylene 182.22
No
N N H2
2-amino-3,5- 252.89N H
dibromopyrazine
Br N Br
N NH2
2-amino-3,5- 251.91dibromopyridine 2
Br Br
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Table 5-1 Compounds with Amide, Primary, Secondary, and Tertiary Amine Groups
(Group I) (Cont'd).
Name Molecular StructureWeight
N NH2
2-amino-5-bromopyrazine 174.00 B N
Br N
N NH,
2-amino-5-bromopyridine 173.01
Br
N NH2
2-aminopyridine 94.11
N
4-(dimethylamino)- 122.17
pyridine N
0
Benzamide 121.14 NH2
0
Isonicotinamide 122.12 NH2
0
Nicotinamide 122.12 NH2
N
4-phenylpyridine 155.20
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Table 5-2 Compounds with Carboxylic Acid Group (Group II).
Name Molecular Weight Structure
0
Oxalic acid 90.03 HO OH
0
0
L-malic acid 134.09 HO OH
O OH
OH 0
L-tartaric acid 150.087 HO OH
O OH
0
Succinic acid 118.09 HO OH
0
o 0
Malonic acid 104.06
HO OH
0
Fumaric acid 116.07 HOy o, OH
0
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Table 5-3 Compounds with Both Carboxylic Acid and Amine Groups (Group III).
Name Molecular StructureWeight
0
2-picolinic acid 123.11 OH
N
0
L-leucine 131.17 OH
NH,
0
L-Lysine 146.19 OH
NH,
0
L-methionine 149.21 S OH
NH
2
0
L-phenylalanine 165.19 OH
NH2
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Table 5-3 Compounds with Both Carboxylic Acid and Amine Groups (Group III)
(Cont'd).
Name Molecular StructureWeight
OH 0
L-threonine 119.12 OH
NH,
H
N
L-tryptophan 204.23 _NH2
OH
0
0
L-histidine 155.15 N OH
HN NH 2
-0
L-isoleucine 131.17 OH
NH2
0
L-valine 117.15 OH
NH2
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Figure 5-4 Comparison between the Powder Pattern of the Cocrystal/4HPG/L-lysine
Mixture and the Powder Patterns of the Individual Components.
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Figure 5-5 Comparison between the Powder Pattern of the Cocrystal/4HPG/Urea
Mixture and the Powder Patterns of the Individual Components.
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Table 5-4 Coformers that Can Form Cocrystals with 4HPG but Not With AMCT.
Name Structure Name Structure
0 HII N
1,1-diethylurea 1 N ) NH2 2-imidazolidone
CNH
0 HN 0
Urea 5-bromo-2(1H)-pyridoneI
H2 N NH 2  Br
H N OH
Imidazole N 2-hydroxypyridine
0
0
2-picolinic acid OH L-leucine OH
N NH2
L-lysine H 2 L-methionine OH
NLo c 
NH2
- 0
L-isoleucine OH
NH2
98
5.2.3 Separation experiments
Three sets of experiments were performed to determine if the coformer could be
used to purify AMCT. In the first experiment, AMCT was crystallized with 4HPG, to
examine how much 4HPG was incorporated into the AMCT crystal lattice (product 1).
In the second experiment, AMCT was crystallized with both the impurity and the
coformer to examine the amount of 4HPG incorporated after the addition of the
coformer (product 2). In the third set of experiments, product 1 was crystallized in fresh
solvent to examine the amount of 4HPG incorporated after two crystallizations from the
initial solution (product 3). In the initial solution, 1.67g of AMCT and 4HPG at 1:10 and
1:5 4HPG:AMCT weight ratios (0.167g and 0.334g, respectively) were dissolved in 100
ml of IM HCl. Coformers were added at a 1:1 4HPG:coformer molar ratio. A 0.45 jim
PTFE syringe filter was used to remove undissolved solids. The pH of the solution was
then adjusted to 4.7 using 5M NaOH followed by a 1-hour wait. The solids obtained
from the crystallization were collected and washed using 2 ml of a 15:85
water/isopropanol mixture. The solids were examined using x-ray powder diffraction
and confirmed to be AMCT. The amount of 4HPG in resulting products was determined
using high performance liquid chromatography (HPLC).
5.2.4 High-Performance Liquid Chromatography
The HPLC instrument (Agilent 1260 Infinity) was equipped with a UV diode
array detector (Agilent Technologies G1315D). The column used was an Agilent
ZORBAX Bonuss-RP 150x4.6 mm I.D. column packed with 5 jim particles (Agilent).
The maximum wavelength for absorbance was set at 230 nm. The concentrations were
analyzed using a 35 min gradient elution program (Table 5-5).48
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Table 5-5 Gradient Elution Program Used.
*A=phosphate buffer solution (0.05M, pH ca.5.9); B=3:1 methanol:acetonitrile.
A liter of 0.05M phosphate buffer solution (pH ca. 5.9) was prepared by
measuring 10 ml of 0.5M K2PO 4 solution and 90 ml of 0.5M KH2 PO 4 solution into a 1 L
volumetric flask, which was then filled with H20 to the mark. The solution was then
thoroughly mixed, degased, and filtered through 0.2 Rm membranes before use.
5.2.5 X-ray Powder Diffraction (XRPD)
Please see section 3.2.7.
5.3 Results and Discussions
5.3.1 Coformer selection
Of the 47 compounds we screened, 13 could form cocrystals with 4HPG.
Carbamazepine and 1,2-bis(4-pyridyl)ethane were able to form cocrystals with AMCT in
addition to with 4HPG and therefore were eliminated from the final list of eleven
coformers (Table 5-4). Of the 47 compounds, there were 31, 6, and 10 in Groups I, II,
and III, respectively. Several factors were examined to determine their effects on the
cocrystal formation: the molecular weight of the compound, the functional group(s) on
the compound, and whether the compound had a phenyl ring or not. The results are
summarized in Table 5-6. For the molecular weight, it was found that 28 compounds had
a molecular weight lower than 150. Ten of these compounds could form cocrystals with
4HPG. Out of the 19 compounds with a molecular weight greater than 150, only three
could form cocrystals with 4HPG; that is, if the compound had a molecular weight lower
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than 150, it had a higher chance of forming cocrystal with 4HPG (35.71% versus
15.79%). When we examined the functional group(s), it was observed that no compound
in Group II could form cocrystals with 4HPG. The probability for a compound in Group
I and III to form cocrystals with 4HPG was 25.9% (8 out of 31 compounds) and 50% (5
out of 10 molecules), respectively; that is, a compound with functional groups that could
form hydrogen bonds with both the carboxylic acid and amine groups on 4HPG had a
better chance of forming cocrystals with 4HPG. Finally, we examined the correlation
between having a phenyl ring in the molecule and its likelihood of forming cocrystals
with 4HPG. The probability of having a phenyl ring and forming cocrystals with 4HPG
was 35.29% (6 out of 17 compounds); the probability of not having a phenyl ring but
forming cocrystals with 4HPG was 23.33% (7 out of 30). This result did not indicate any
clear correlation.
101
Table 5-6 Numbers of Coformers in Different Groups Characterized by Molecular
Weight (MW), Structures, and the Existence of Phenyl Ring.
MW < 150 MW > 150 Total #
#of #of #of #of
Coformers Compounds Coformers Compounds Coformers Compounds
Group I 5 16 1 15 6 31
no phenyl 2 5 0 0 2 5
ring
w/ phenyl 3 11 1 15 4 26
ring
Group II 0 5 0 1 0 6
no phenyl 0 5 0 1 0 6
ring
Group III 5 7 0 3 5 10
no phenyl 4 6 4 6
ring
w/ phenyl 1 1 0 3 1 4
ring
Grand Total 10 28 1 19 11 47
5.3.2 Separation experiments
Separation experiments were performed at a 1:10 4HPG:AMCT weight ratio. If
coformers were added, a 1:1 4HPG:coformer molar ratio was used. The amounts of
4HPG incorporated into AMCT obtained from the crystallization experiments are
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presented in Table 5-7. The mass percentage of 4HPG in AMCT crystals after the initial
crystallization was 0.98(±0.071) wt%. After a second crystallization (using fresh
solvent), the amount of 4HPG decreased to 0.42(±0.053) wt%. With the addition of 2-
imidazolidone, urea, and L-methionine, the amount of 4HPG incorporated into AMCT
crystal lattices after the initial crystallization increased to 2.45(±0.035) wt%,
1.52(±0.094) wt%, and 1.28(±0.053) wt%, respectively. The addition of 1,1-diethylurea,
imidazole, 2-hydroxypyridine, and 5-bromo-2(1H)-pyridone decreased the amount of
4HPG after an initial crystallization to 0.94(±0.069) wt%, 0.72(±0.009) wt%,
0.6(±O.048) wt%, and 0.36(±0.035) wt%, respectively. The best separation was obtained
from four compounds: 2-picolinic acid, L-lysine, L-isoeucine, and L-leucine where the
amount of 4HPG in the AMCT crystal after one crystallization decreased to
0.17(±0.0056) wt%, 0.17(±0.0049) wt%, 0.15(±0.0023) wt%, and 0.12(±0.097) wt%,
respectively.
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Table 5-7 Amounts of 4HPG in AMCT from Crystallization
Weight Ratio of 4HPG:AMCT.
Experiments with a 1:10
Amount of 4HPG Decreased
(%) (%)
Only 4HPG 0.98±0.071
Second crystallization 0.42±0.053 57.14
2-Imidazolidone 2.45±0.035 -150
Urea 1.52±0.094 -55.1
L-Methionine 1.28±0.053 -30.6
1,1-Diethylurea 0.94+0.069 4.1
Imidazole 0.72±0.009 26.5
2-Hydroxypyrdine 0.6±0.048 38.8
5-Bromo-2(lH)-pyridone 0.36±0.035 63.3
2-Picolinic acid 0.17+0.0056 82.7
L-Lysine 0.17+0.0049 82.7
L-Isoleucine 0.15±0.0023 84.7
L-Leucine 0.12±0.0097 87.8
To investigate the effect of the initial impurity concentration on the amount of
impurity incorporated into the crystal lattice of the target compound, 4HPG was added at
a weight ratio of 1:5 to AMCT. The amount of 4HPG in AMCT crystals was
1.13(±0.077) wt%. Compared to the result where the initial molar ratio was 1:10, the
amount of 4HPG did not increase significantly.
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5.3.3 The effect of varying the amount of the coformer added
We also investigated the effect of varying the amount of coformer added on the
purification results using the four compounds that purify AMCT the most: 2-picolinic
acid, L-lysine, L-isoleucine, and L-leucine. For each coformer, four coformer-to-4HPG
molar ratios (r) were studied: r=0.1, 0.5, 1, and 1.5. Purification results in terms of the
amount of 4HPG incorporated into the AMCT crystal lattice are shown in Figure 5-6.
Two trends were observed. In the 2-picolinic acid and L-lysine systems, no significant
differences were observed for r=O.1 (0.92(±0.0069) wt% and 0.89(±0.074) wt%,
respectively.) The amount of incorporated 4HPG decreased dramatically when r=0.5
(0.16(±0.0084) wt% and 0.15(±0.0048) wt%, for 2-picolinic acid and L-lysine,
respectively) and no further decrease was observed with the increasing amount of the
coformer added (for r-1, 0.17(±0.0056) wt% and 0.17(±0.0049) wt%, for 2-picolinic
acid and L-lysine, respectively; for r-1.5, 0.15(±0.0075) wt% and 0.18(±0.0087) wt%,
for 2-picolinic acid and L-lysine, respectively). A different trend was observed in the L-
leucine and L-isoleucine systems. In the L-leucine system, the amount of 4HPG
decreased from 0.87(±0.057) wt% to 0.12±(0.00097) wt% when r increased from 0.1 to
1. Similarly, the amount of 4HPG decreased from 0.79±(0.083) wt% to 0.15(±0.0023)
wt% with increasing r (from 0.1 to 1) in the L-isoleucine system. The additional
coformer (r--1.5) did not further decrease the amount of 4HPG in AMCT crystals
(0.13(A0.01 1) wt% for the L-leucine system and 0.12(±0.0046) wt% for the L-isoleucine
system).
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Figure 5-6 The Effect of Coformer Amount Added on the Amount of 4HPG
Incorporated into AMCT Crystal Lattices.
To summarize, 47 compounds were selected and examined using solid-state
grinding. Eleven were found to form cocrystals with 4HPG but not with AMCT.
Separation experiments were performed and the addition of four compounds (2-picolinic
acid, L-lysine, L-leucine, and L-isoleucine) decreased the amount of 4HPG incorporated
into AMCT crystal lattices the most. By varying the amount of the coformer added, the
optimal coformer-to-4HPG molar ratio was found to be 0.5 for the 2-picolinic acid and
L-lysine systems and to be 1 for the L-leucine and L-isoleucine systems. Further
addition of coformers beyond a certain point did not have a significant effect on the
amount of 4HPG incorporated into the crystal lattices of AMCT.
5.3.4 Discussions
Three characteristics of compounds were examined to find their effects on the
formation of 4HPG cocrystal: molecular weight, different types of functional groups,
and the presence of a phenyl ring in the chemical structure. It was found that if the
compound had a molecular weight smaller than 150, it had a higher chance of forming
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cocrystal with 4HPG. This observation can be explained by the steric effect. The greater
the molecular weight, the larger the molecule. Hence, the steric effect would hinder the
interaction between the functional groups on the coformer candidate and on 4HPG
during the formation of a crystalline material. It was found that compounds with both
carboxylic acid and amine groups had a high probability of forming cocrystals with
4HPG. This observation fits the general rules for hydrogen bonding in cocrystals
established by Etter.17 She analyzed the cocrystal patterns as a result of
intra/intermolecular interactions and found that six-membered ring hydrogen bonds
formed between different molecules have a higher priority than non-cyclic hydrogen
bonding. Therefore, when the coformer functional groups can form cyclic hydrogen
bonds with the carboxylic acid and amine group on 4HPG, they have a higher chance of
forming cocrystals with 4HPG. As for the phenyl ring, no clear correlation was observed
between the presence of a phenyl ring and the cocrystal formation. Intra/intermolecular
t-n interactions between two phenyl rings either on the same or different components
have been found in cocrystals.s1 ,5 2-56 However, compared to hydrogen bonds, 7[-7E
interactions are weak interactions and should never be used as the main design principle.
Sometimes the presence of phenyl rings can have a steric effect and prevent two
components from forming cocrystals. We can conclude that the steric effect and
functional groups on coformer candidates are the two most important factors when we
design cocrystals.
For the eleven coformers with which separation experiments were performed, 2-
picolinic acid, L-lysine, L-leucine, and L-isoleucine enhanced the AMCT purity the
most. Compared to all other coformers whose functional group could only interact with
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one functional group on 4HPG, these compounds have functional groups that can
interact with both functional groups on 4HPG to form cyclic hydrogen bonds. According
to Etter's hydrogen bonding rules, cyclic hydrogen bonding is always preferred to single
hydrogen bonding. We assumed that the stronger the coformer interacts with 4HPG in
the solid state, the higher the probability that the coformer would form complexes with
the impurity in solution; and therefore, high amounts of complexes must form between
these four coformers and 4HPG. High levels of complexation contributed to the
enhancement of purification.
The purification results obtained from a single crystallization reduced the
impurity concentration to as low as 0.12(±0.0097) wt% from 0.98(±0.071) wt% when no
coformer was added. In addition, crystals made from a second crystallization without the
coformer were still significantly less pure than crystals made from a single
crystallization with the coformer. This result indicates the potential usefulness of the
method. The most common way to improve product purity is to recrystallize the
compound of interest. However, by doing so, the yield is sacrificed. In contrast, in our
separation method, in addition to the high purity gained, the yield was not sacrificed.
Our proposed separation method thus has the potential to be applied for expensive
products when low yield is unacceptable.
We can correlate the level of complexation to the purification results with the
addition of various coformer amounts. At r=O. 1, no significant decrease was observed in
any system. This could be due to the lack of complex formation. For the 2-picolinic acid
and L-lysine systems, the best purifications were achieved at r=0.5 and additional
coformers did not further decrease the amount of 4HPG in AMCT crystal lattices. This
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fact suggested that the level of complexation increased when r was increased from 0.1 to
0.5 and that the maximum level of complexation was achieved at r-0.5. The optimum
coformer-to-4HPG molar ratio for these two systems was at r=0.5 since we could
achieve the best purification without adding excess amounts of coformers. For the L-
leucine and L-isoleucine systems, the amount of 4HPG decreased with increasing r
(from 0.1 to 0.5 and 1), indicating that the level of complexation increased with the
increasing amount of coformers added. The fact that no further purification was
observed when the additional coformer was added (after r-0.5 for 2-picolinic and L-
lysine systems and after r=1 for L-leucine and L-isoleucine systems.) implied that the
maximum level of complexation was achieved.
5.3.5 Summary
With these observations, we verified the practical use of our proposed separation
method with AMCT/4HPG as our model system. General rules for cocrystal formation
were established. Separation results with various amounts of coformers suggested that
the purification was due to the interaction between the coformer and 4HPG, and the
level of complexation in solution.
5.4 Conclusions
In this work, we evaluated the practical use of the proposed separation method
with a real drug/impurity system. Without advance knowledge of cocrystal formation of
4HPG, coformers were identified to reduce the amount of 4HPG incorporated into
AMCT crystals greatly. Forty-seven compounds were selected because they had
functional groups that could form synthons with functional groups on 4HPG. Eleven
were confirmed to form cocrystals with 4HPG but not with AMCT using solid-state
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grinding. Separation experiments were performed and four compounds were found to
decrease the amount of 4HPG incorporated into AMCT crystal lattices the most: 2-
picolinic acid, L-leucine, L-isoleucine, and L-lysine. The amounts of 4HPG incorporated
in AMCT in these four systems were lower than that for samples of AMCT produced
through two crystallizations. The optimal amount of coformers needed to achieve the
best purification was found. We were able to correlate purification results to the level of
complexation by varying the amount of coformers added.
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6. THE SEPARATION OF IMPURITIES FROM SOLUTION
USING SELF-ASSEMBLED MONOLAYERS (SAMS) ON
GOLD SURFACES
6.1 Introduction
In this work, we applied the same principle, molecular recognition, to separate
the impurity from the target. However, instead of focusing on the molecular recognition
between the impurity and the coformer, we now focus on the interaction between the
impurity and a functionalized surface.
The aim of this work is to separate the impurity from the target using
functionalized surfaces that can selectively adsorb the impurity in solution. The surfaces
were functionalized so that their functional groups had the potential to form hydrogen
bonds with the functional group on the impurity but not with the functional group on the
target. Therefore, we hypothesized that when a functionalized surface immersed into an
impurity/target mixture would selectively bind the impurity and leave the target in
solution. We functionalized the gold surfaces by depositing self-assembled monolayers
on them. Self-assembled monolayers (SAMs) refer to the spontaneous adsorption of
molecules from solution to form an oriented monolayer film on a surface.57 SAMs
consist of a head group, an alkyl chain and a tail group (Figure 6-1). The head group is
adsorbed onto substrates followed by the formation of covalent bonds; the alkyl chains
then slowly arrange into an ordered monolayer. The tail group is then exposed to the
solid-liquid or solid-vapor interfaces and hence functionalizes the surface. Common
head groups include thiols, silanes, and phosphonates and they can be deposited on
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different substrates. In our work, thiols (organosulfur compounds) were chosen because
of their high structural order, their flexibility in the structure of functional groups
exposed at the solid-vapor or solid-liquid interface, and the ease of preparation and
analysis.58 Many studies have been done on the preparation and structural
characterization of thiols.5 9-61 58'62 It was found that by varying the length of the alkyl
chain and the head group, tail group and solvent, the chemistry, structure, and properties
of the surface could be controlled.58 63'64 The structures of SAMs were studied using
transmission electron microscopy and diffraction techniques, reflection infrared
spectroscopy, scanning tunneling microscopy, x-ray photoelectron spectroscopies,
ellipsometry and wetting. 61,62,65-67 It is a particular interest to relate the microscopic
structure of SAMs to their physical, chemical, and biological properties (wettability,
corrosion resistance, adhesive strength, and biocompatibility). 68,69 With control over the
wettability, adhesion, tribology, and corrosion, SAMs have been commonly used as
photoresists, in promoting adhesion, in microelectronics, photochemical and
electrochemical processes, and in modeling biological interfaces. 69' 70 Studies have also
shown that functionalized SAMs on gold surfaces can selectively bind the target that is
recognized by the functional group on the surface.71 72
R R R Tail Group
Alkyl Chain
Head Group
Substrate
Figure 6-1 Representation of SAMs on the Substrate.
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To achieve our goal, we manufactured gold surfaces with different functional
groups and evaluated their abilities to adsorb an impurity from solution selectively. Two
thiol molecules, 4-mercapto pyridine and 2-mercapto benzimidazole, were used to
manufacture functionalized gold surfaces. Three systems, IBU/KETO in toluene,
BA/BAM in ethanol, and CA/CAM in ethanol were chosen to evaluate the performance
of the functionalized gold surfaces. Separation experiments were performed and the
purities of the resulting solution were measured using HPLC. The performances of these
gold surfaces were determined using the impurity-to-target concentration ratio in
solution over time. If the gold surfaces could selectively adsorb the impurity, the
impurity-to-target concentration ratio in solution would be lower than that in the initial
solution and would decrease over time until the gold surfaces became saturated and no
longer of adsorbing any more molecules. After that point, the impurity-to-target
concentration ratio should remain the same. The results are presented in Figure 6-3,
Figure 6-4, Figure 6-5, Figure 6-6, and Figure 6-7. Large variances were observed and
no significant results were obtained. Because the concentration of the impurity and the
target were too low in the wash, the impurity-to-target ratio absorbed on the gold
surfaces (that ideally should be higher than that in the initial solution), could not be used
to determine the performance of the gold surfaces.
In this work, we evaluated the potential of purifying impurity/target mixtures
using functionalized SAMs on gold surfaces. For the three systems studied, large
variances between the repeats were observed and no significant separation was obtained.
Possible modifications to the apparatus, experimental setup, and system selection are
113
suggested and the amount of future work needed to verify the possibility of this
separation method is significant.
6.2 Materials and Methods
6.2.1 Materials
Benzoic acid (BA, ACS reagent, >_ 99.5%), benzamide (BAM, 99%), trans-
cinnamic acid (CA, > 99%), cinnamamide (CAM, predominately trans, 97%), ibuprofen
(IBU, > 98%), ketoprofen (KETO, > 98%), 4-mercapto pyridine (> 95%), and 2-
mercapto benzimidazole (> 97%) were purchased from Sigma-Aldrich and were used as
received. Gold coated test slides (float glass size: 1" x 3" x .040", coating: 50 A of
titanium followed by 1,000 A gold, > 99.9%) were purchased from emf.
Sulfuric acid (95-98%, ACS reagent) and hydrogen peroxide (30 wt% in water,
ACS reagent) were purchased from Sigma-Aldrich and used to prepare piranha solution.
Anhydrous ethanol (200 proof) was USP grade and was purchased from VWR.
Methanol (MeOH, CHROMASOLV* for HPLC >_ 99%), acetonitrile (ACN,
CHROMASOLV* for HPLC > 99%) and water (H20, CHROMASOLV* Plus for
HPLC) were purchased from Sigma-Aldrich and used for HPLC.
6.2.2 System selection
Three model systems, IBU/KETO in toluene, BA/BAM in ethanol, and
CA/CAM in ethanol were chosen because they were studied in previous approaches.
Toluene was chosen to be the solvent because it is a non-polar solvent that does not
interfere with the hydrogen bond formation between the functionalized SAMs and the
impurity. It was not used for the BA/BAM and CA/CAM system because all compounds
were only sparingly soluble in it. Two thiol molecules, 4-mercapto pyridine and 2-
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mercapto benzimidazole were chosen to synthesize SAMs on gold surfaces. Their
structures are shown in Figure 6-2. The secondary and tertiary amine group on 2-
mercapto benzimidazole and the tertiary amine group on 4-mercapto pyridine have the
potential to form hydrogen bonds with the carboxylic acid groups on IBU, BA and CA.
Although they have similar functional groups, the location of the functional group in
these two thiol molecules is different. While the tertiary amine group on 4-mercapto
pyridine is exposed on the gold surface, the secondary and tertiary amine groups on 2-
mercapto benzimidazole are close to the gold surfaces and hindered by a phenyl ring. It
is our interest to see if the steric effect would affect the performance of the
functionalized gold surfaces.
H SHN
SH
N N
(a) (b)
Figure 6-2 Structures of (a) 2-mercapto benzimidazole (b) and 4-mercapto pyridine.
6.2.3 SAM preparation
Piranha solution (3:1 v:v sulfuric acid: hydrogen peroxide) was made by slowly
adding hydrogen peroxide to sulfuric acid and allowing the mixture to reach room
temperature over the course of an hour. Gold surfaces were immersed into the piranha
solution for an hour to clean and then washed with water and isopropanol using a squirt
bottle. These gold surfaces were blow-dried using a nitrogen gun and were subsequently
ready for the thiol deposition.
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Two thiols, 4-mercapto pyridine and 2-mercapto benzimidazole, were dissolved
in ethanol to prepare 10mM solutions. Clean gold surfaces were immersed into thiol
solutions for thiol deposition and the solution was degased overnight with N2. The gold
surfaces were washed with ethanol and blow-dried with a nitrogen gun, after which thet
were functionalized and ready for use.
6.2.4 Selectivity and separation experiments
Staining dishes that could hold 20 slides were purchased from VWR and used to
hold functionalized gold slides. Different functionalized gold slides were aligned on the
slide holder and immersed into a target/impurity mixture for various time periods.
Samples were taken every 10-30 mins for HPLC analysis as follows. Gold surfaces were
gently washed with ethanol first to remove the solution retained on the surface. The
wash was recollected to avoid the loss of the impurity or the target compound. The
amount of solvent used to wash gold surfaces was recorded. The gold surfaces were then
placed in ethanol and sonicated for 20 mins to remove the bound impurity or the target
compound. Finally, gold surfaces were regenerated after they were washed using ethanol
and dried with N2.
6.2.5 High-Performance Liquid Chromatography
For the IBU/KETO system, the method described in section 3.2.6 was followed.
For the BA/BAM and CA/CAM system, the method described in section 4.2.5 was
followed.
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6.3 Results and Discussions
6.3.1 Separation experiments
Various factors, including the functional groups on the thiol molecules and the
experimental time, were studied to determine their effects on the purification results.
Large variances were observed among separation experiments with the same conditions
(the same impurity/target system, the same functionalized gold surfaces, and the same
time period). A set of separation results of three systems, IBU/KETO in toluene (over
150 mins), BA/BAM in ethanol (over 8 hours), and CA/CAM in ethanol (over 8 hours)
using 4-mercapto pyridine and 2-mercapto benzimidazole chips are shown in Figure 6-3
to Figure 6-7. A t-test was performed to decide if a significant decrease was present in
the impurity-to-target concentration ratio over time. Large variances between repeats
were observed and no significant decrease was obtained over a long time period (from
150 minutes to 8 hours).
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Figure 6-3 Separation Results of IBU/KETO in Toluene Using 4-mercapto Pyridine
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Figure 6-4 Separation Results of BA/BAM in Ethanol Using 4-mercapto Pyridine Chips.
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Figure 6-5 Separation Results of BA/BAM in Ethanol Using 2-mercapto Benzimidazole
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Figure 6-6 Separation Results of CA/CAM in Ethanol Using 4-mercapto Pyridine Chips.
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Figure 6-7 Separation Results of CA/CAM in Ethanol Using 2-mercapto Benzimidazole
Chips.
6.3.2 Discussions
The large variability among the purification results could be due to the
evaporation of solvents from the sample. Despite the fact that the apparatus was sealed
using parafilm, it was observed that evaporation still occurred during the sampling stage
and over time. Modifications should be made to the apparatus to prevent evaporation.
The fact that no significant purification was shown can be due to several reasons. First,
the solvent used in the BA/BAM and CA/CAM systems, ethanol, can interfere with the
hydrogen bond formation between the impurity and the functionalized gold surfaces. We
suggest choosing systems with non-polar solvents in which both the impurity and the
target are soluble. Second, the surface area of these functionalized surfaces is limited.
Modifications should be made to increase the surface area dramatically to achieve
detectable purification. Third, we can conclude that the lack of purification was due to
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the lack the selectivity of the functionalized gold surfaces. It is suggested to choose thiol
molecules that can form stronger hydrogen bonds with the functional group on the
impurity.
6.3.3 Summary
For the three systems we studied, we did not observe any repeatable promising
purification. Despite our attempts to modify the apparatus, the experimental setup, or the
solvent, this separation method was unsuccessful. Several suggestions were made for
future research.
6.4 Conclusions
We investigated the possibility of separating impurities from the solution using
functionalized SAMs on gold surfaces. Three impurity/target compound systems:
IBU/KETO in toluene, BA/BAM in ethanol and CA/CAM in ethanol were studied. Two
thiol molecules were chosen to bind the impurity selectively: 2-mercapto benzimidazole
and 4-mercapto pyridine. After initial promising results shown in previous work,
carefully repeated experiments show no significant separation in all three systems. We
concluded that this result was likely due to solvent evaporation, solvent interference, the
limited surface area, and the lack of selectivity of the SAMs for the impurities.
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7. CONCLUSIONS AND FUTURE WORK
7.1 Conclusions
This thesis focuses on the study and optimization of separation processes that
aim to (1) avoid crystallization, filtration and re-dissolution of the target compound by
the selective removal of the impurity from solution and (2) enhance the selectivity of the
crystallization in cases where the impurity substitutes into the crystalline lattice by the
complexation of impurities in solution. We targeted the separation of structurally similar
compounds and studied three approaches: (1) selective impurity cocrystal formation; (2)
selective impurity complex formation in solution; and (3) selective adsorption of
impurity from solution using functionalized self-assembled monolayers (SAMs) on gold.
All approaches were designed based on molecular recognition, utilizing the differences
between the functional groups on the impurity and on the target compound.
In the first approach, a coformer that can form cocrystals with the impurity but
not with the target compound was added to the impurity/target mixture. The impurity
cocrystal precipitates since it has a reduced solubility compared to the impurity itself.
The purified solution can then go for downstream processing. A strategy was established
to choose the optimal coformer, concentration of the coformer, and solvent for a specific
impurity/target system and was demonstrated using the ibuprofen/ketoprofen system.
While it was found that the amount of ibuprofen in solution decreased significantly, the
amount remaining was still larger than desired. In addition, the coformer was present in
the final purified solution. Several attempts to decrease the amount of the impurity and
the coformer in solution further were made but none showed significant improvement.
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The second approach targets systems where the impurity is incorporated into the
crystal lattice of the target compound. A coformer that can form a cocrystal with the
impurity but not with the target compound was added to the impurity/target mixture to
form complexes with the impurity and hence prevent its incorporation into the target
compound. Three systems were studied to demonstrate the effectiveness of this approach
and to show the correlation between the level of the complexation and the purification
results. The first two systems were benzoic acid/benzamide and cinnamic
acid/cinnamamide. In each system, the target and the impurity are structurally similar
compounds where the impurity incorporates into crystal lattices of the target compound.
In both systems, particular coformers were known to form cocrystals with the impurity.
It was found that the structurally similar compounds could be purified by adding these
coformers that could form cocrystals with the impurity. However, no clear correlation
between the level of complexation and the purification results were found. A real
drug/impurity system, amoxicillin trihydrate/4-hydroxyphenylglycine for which no
coformer was known to form cocrystals with the impurity was used to examine the
practical use of this approach further, the work flow that would be employed, and the
purification that might be obtained due to the complex formation in solution. The
purification results after the addition of coformers were better than that obtained after
two crystallizations. Hence, this method has been shown to be successful with potential
practical use. In addition, it was found that by increasing the amount of the coformer
added, the amount of the impurity in target crystals decreased with an optimal amount
for each of the successful coformers. This result implies that the more complexes are
formed, the less incorporation of the impurity into target crystal lattices occurs.
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The third approach was to adsorb impurities using functionalized gold surfaces
selectively. Thiol molecules with functional groups that could form hydrogen bonds with
the functional group on the impurity were used to functionalize the gold surfaces. We
hypothesized that by immersing these gold surfaces in solution, the impurity would
selectively adsorb onto the surfaces and thus be removed from solution. In the three
systems studied, large variances were observed and no significant purification was
obtained, which is likely due to the lack of selectivity of the functionalized gold
surfaces.
7.2 Future Work
In this study, we successfully developed two potential separation methods that
could be used for intermediate and final product purifications. Though both showed the
potential for practical usage, improvements can be made to accelerate the coformer
selection process and enhance the purification further.
The current coformer selection process includes (1) a search in the CSD for
reported heterosynthons which include the functional group on the impurity, (2) solid-
state grinding to find compounds that can potentially form cocrystals with the impurity,
(3) solution crystallization to make pure cocrystals and (4) solubility measurement to
determine the solubility of all components. This process is very labor-intensive and
involves a significant amount of trial and error. A computational method is desired to
predict whether a compound can form cocrystals with the impurity and the solubility of
the impurity cocrystal. For example, it could be possible to predict the formation of
cocrystals between two components by calculating the energy decrease when two
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components interact with each other. It is also possible to predict the cocrystal solubility
by applying thermodynamic models.
For the first approach, more research should be done to decrease the amount of
the impurity and the coformer left in the solution further. The amount of the impurity
and the coformer left in the solution is limited by the solubility of the impurity cocrystal,
which is affected by the operating solvent and temperature. A tradeoff between the yield
and the purity was observed in our system when a cooling process was applied.
However, the operating conditions would be system specific. It is suggested that a
combination of cooling and the addition of anti-solvent should be investigated for
potential improvements.
For the second approach, it is desired to quantify the level of complexation in
solution and to use that information as a tool to predict the purification results. Attempts
were made to quantify the level of complexation using different spectroscopies
(including raman spectroscopy, ultraviolet-visible spectroscopy, and infrared
spectroscopy) and nuclear magnetic resonance (NMR) but none were successful due to
difficulty in deconvoluting individual contributions, solvent interference, and instrument
limitation. Investigation into new technologies would be of great help.
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9. APPENDIX I.
9.1 X-ray Powder Diffraction Patterns for 4HPG Cocrystals
In this appendix, we presented the powder patterns of thirteen
cocrystal/impurity/coformer mixture obtained by grinding 4HPG with coformer at a one-
to-one molar ratio. Arrows in the graph indicate new peaks that belong to the cocrystal.
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Figure 9-1 Comparison between the Powder Pattern of the Cocrystal/4HPG/ 1, 1-
diehtylurea Mixture and the Powder Patterns of the Individual Components.
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Figure 9-2 Comparison between the Powder Pattern of the Cocrystal/4HPG/1,2-bis(4-
pyridyl)ethane Mixture and the Powder Patterns of the Individual Components.
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Figure 9-3 Comparison between the Powder Pattern of the Cocrystal/4HPG/2-
hydroxypyridine and the Powder Patterns of the Individual Components.
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Figure 9-4 Comparison between the Powder Pattern of the Cocrystal/4HPG/2-
imidazolidone Mixture and the Powder Patterns of the Individual Components.
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Figure 9-5 Comparison between the Powder Pattern of the Cocrystal/4HPG/2-picolinic
acid Mixture and the Powder Patterns of the Individual Components.
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Figure 9-6 Comparison between the Powder Pattern of the
2(1H)-pyridone Mixture and the Powder Patterns of the
Cocrystal/4HPG/5-bromo-
Individual Components.
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Figure 9-7 Comparison between the Powder Pattern of the
Cocrystal/4HPG/Carbamazepine Mixture and the Powder Patterns of the Individual
Components.
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Figure 9-8 Comparison between the Powder Pattern of the Cocrystal/4HPG/L-isoleucine
Mixture and the Powder Patterns of the Individual Components.
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Figure 9-9 Comparison between the Powder Pattern of the Cocrystal/4HPG/L-leucine
Mixture and the Powder Patterns of the Individual Components.
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Figure 9-10 Comparison between the Powder Pattern of the Cocrystal/4HPG/L-lysine
Mixture and the Powder Patterns of the Individual Components
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Figure 9-11 Comparison between the Powder Pattern of the Cocrystal/4HPG/L-
methionine Mixture and the Powder Patterns of the Individual Components.
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Figure 9-12 Comparison between the Powder Pattern of the Cocrystal/4HPG/Urea
Mixture and the Powder Patterns of the Individual Components.
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Figure 9-13 Comparison between the Powder Pattern of the Cocrystal/4HPG/Imidazole
Mixture and the Powder Patterns of the Individual Components.
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